| acetylcysteine versus placebo | |||
| Tepel, 2003 | acetylcysteine 600 mg twice daily versus placebo | patients undergoing maintenance hemodialysis for a minimum of 3 months 3 times weekly in an ambulatory center | double-blind Follow-up duration: 14.5 y Germany |
| aggressive cholesterol-lowering versus moderate cholesterol-lowering | |||
| Post CABG (diabetic sub group), 1999 | aggressive cholesterol-lowering versus moderate cholesterol-lowering | patients 1-11 years after CABG | double blind |
| aggressive treatment versus standard teatment | |||
| SANDS, 2008 NCT00047424 | aggressive targets of LDL-C of 70 mg/dL or lower and SBP of 115 mm Hg or lower versus standard targets of LDL-C of 100 mg/dL or lower and SBP of 130 mm Hg or lower | adults with type 2 diabetes | open Follow-up duration: 3 years US |
| alirocumab versus ezetimibe (on top statin) | |||
| ODYSSEY OPTIONS I, | Alirocumab 75 mg with potential up-titration to 150 mg Q2W versus Ezetimibe 10 mg | high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg) | Follow-up duration: 24 wk |
| ODYSSEY OPTIONS II, | Alirocumab 75 mg with potential up-titration to 150 mg Q2W versus Ezetimibe 10 mg | high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg) | Follow-up duration: 24 wk |
| alirocumab versus ezetimibe alone | |||
| ODYSSEY MONO, NCT01644474 | Alirocumab 75 mg Q2W versus Ezetimibe 10 mg | hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy | double-blind Follow-up duration: 24 wk |
| alirocumab versus placebo (on top statins) | |||
| ODYSSEY Alternative, NCT01709513 | Alirocumab 75 mg with potential up-titration to 150 mg Q2W versus Ezetimibe 10 mg | statin-intolerant patients | double-blind Follow-up duration: 24 wk |
| ODYSSEY COMBO, NCT01644175 | Alirocumab 75 mg with potential up-titration to 150 mg Q2W versus Placebo | high cardiovascular risk patients on maximally tolerated statin therapy | double-blind Follow-up duration: 52 wk |
| ODYSSEY COMBO II, NCT01644188 | Alirocumab 75 mg with potential up-titration to 150 mg Q2W versus Ezetimibe 10 mg | high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins | double-blind Follow-up duration: 104 wk |
| ODYSSEY FH 1, NCT01623115 | Alirocumab 75 mg with potential up-titration to 150 mg Q2W versus Placebo | patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy | double-blind Follow-up duration: 78 wk |
| ODYSSEY FH 2, NCT01709500 | Alirocumab 75 mg with potential up-titration to 150 mg Q2W versus Placebo | patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy | double blind Follow-up duration: 78 wk |
| ODYSSEY HIGH FH , NCT01617655 | Alirocumab 150 mg Q2W versus Placebo | patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy | Follow-up duration: 52–78 wk |
| ODYSSEY Long-Term, 2015 NCT01507831 | alirocumab 150 mg as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. versus placebo | patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy | Follow-up duration: 78 wk |
| ODYSSEY OUTCOMES, 2018 NCT01663402 | Alirocumab (on top intensive or maximum-tolerated statin therapy) versus placebo | Post-ACS patients (1 to 12 months)with elevated levels of atherogenic lipoproteins despite intensive or maximum-tolerated statin therapy | double-blind Follow-up duration: 2.8 yr (median) 57 countries |
| alpha-linolenic acid versus placebo | |||
| ALPHA OMEGA (ALA), 2010 NCT00127452 | margarine supplemented with plant-derived alpha-linolenic acid (with a targeted additional daily intake of 2 g of ALA) versus placebo | men and women with a history of myocardial infarction | double-blind Follow-up duration: 40 months the Netherlands |
| Natvig, 1968 | linseed oil, 10 ml /d (55% a-linolenic acid) versus placebo (sunflower oil, 10 ml/d (1.4% a-linolenic acid)) | working men, though a few had had a previous MI or angina7ieªôq” | double-blind Follow-up duration: 12 months Norway |
| anacetrapib versus placebo | |||
| DEFINE, 2010 NCT00685776 | anacetrapib 100mg fr 18 months versus placebo | patients with coronary heart disease or at high risk for coronary heart disease | double-blind 20 countries |
| REVEAL HPS-3 TIMI-55, 2017 NCT01252953 | anacetrapib 100mg daily versus placebo | high risk patients already taking statins | double-blind Follow-up duration: median 4 years |
| REALIZE, 2015 NCT01524289 | oral anacetrapib 100 mg for 52 weeks versus placebo | patients aged 18-80 years with a genotype-confirmed or clinical diagnosis of heterozygous familial hypercholesterolaemia, on optimum lipid-lowering treatment for at least 6 weeks, and with an LDL-C concentration of 2·59 mmol/L or higher without cardiovascular disease or 1·81 mmol/L or higher with cardiovascular disease | double-blind Follow-up duration: 52 weeks |
| anticoagulant versus no anticoagulant | |||
| MacMillan, 1960 | versus | ||
| Borchegrevink, 1960 | versus | ||
| Clausen, 1961 | versus | ||
| Harvald, 1961 | versus | ||
| Conrad, 1964 | versus | ||
| Wasserman, 1966 | versus | ||
| Loeliger, 1967 | versus | ||
| Lovell, 1967 | versus | ||
| Seaman, 1969 | versus | ||
| Sorensen, 1969 | versus | ||
| Meuwisse,, 1969 | versus | ||
| Drapkin and Merskey, 1972 | versus | ||
| any statin versus no statin | |||
| Sakamoto, 2006 | any available statin versus no statin | Japanese patients with AMI within 96 hours of AMI onset | open Follow-up duration: up to 24 months Japan |
| aspirin versus no treatment | |||
| British Doctor’s Trial, 1988 | aspirin 500 mg/d versus no aspirin | apparently healthy male doctors | open Follow-up duration: 5.5 years UK |
| PPP (diabetics sub group), 2003 | aspirin 100mg daily versus control | men and women with diabetes and without a previous cardiovascular event aged >50 with >=1 risk factors for cardiovascular disease - sub group of diabetic patients | open Follow-up duration: 3.6 y Italy |
| Primary Prevention Project, 2001 | aspirin 100 mg/d versus no aspirin (open control) | men and women aged 50 years or greater, with at least one of the major recognised cardiovascular risk factors. | Open Follow-up duration: 3.6 y Italy |
| JPAD, 2008 NCT00110448 | low-dose aspirin (81 or 100 mg per day) versus no aspirin | patients with type 2 diabetes without a history of atherosclerotic disease | open Follow-up duration: 4.37 y median Japan |
| aspirin versus placebo | |||
| AAA, 2009 ISRCTN66587262 | aspirin 100mg daily versus placebo | men and women aged 50 to 80 years with asymptomatic atherosclerosis detected by low ankle brachial index (<=0.95) | double blind Follow-up duration: 8.2 y (mean) UK, Scotland |
| ASPREE, 2018 NCT01038583 | versus | ||
| ASCEND, 2018 NCT00135226 | versus | ||
| CLIPS, 2007 | oral aspirin 100 mg daily versus placebo | outpatients with stage I-II PAD documented by angiography or ultrasound, with ankle/brachial index <0.85 or toe index <0.6 | double blind Follow-up duration: 20.7 months mean Europe |
| PHS (diabetics sub group), 1989 | aspirin 325 mg every other day versus placebo | healthy men (diabetic sub group of patients enrolled if PHS) | double blind Follow-up duration: 5 y |
| Physicians Health Study, 1989 NCT00000500 | aspirin 325 mg every other day versus placebo | Healthy men | double blind Follow-up duration: 60.2 months |
| Munich B, 1975 | Aspirine 1500 mg / jour pendant 24 mois versus Placebo | NA | double blind |
| ETDRS, 1992 | aspirin 650mg once daily versus placebo | patients with diabetes mellitus (Type I or II) | double blind Follow-up duration: 60 months |
| Thrombosis Prevention Trial, 1998 NCT00000614 | aspirin 75 mg/d (controlled release) versus placebo | Men at high risk of CHD | double blind Follow-up duration: median 6.8y UK |
| HOT, 1998 | aspirin 75 mg daily versus placebo | patients aged 50-80 with hypertension and diastolic blood pressure between 100 mmHG and 115 mmHG | Double blind Follow-up duration: mean 3.8 y (range 3.3-4.9y) Europe, North and South America, and Asia |
| Munich A, 1975 | Aspirine: 1500 mg / jour versus Placebo | Données non disponibles | double blind |
| CDPA, 1976 | Aspirin (324 mg) 3x/d versus Placebo | MI survivors | Double blind Follow-up duration: 1.83 y USA |
| Cardiff I, 1974 | Aspirin (300 mg) 1x/d versus Placebo | MI survivors | Double blind Follow-up duration: 2 years UK |
| Cardiff II, 1979 | Aspirin (300 mg) 3x/d for one year versus Placebo | patients with myocardial infarction | Double blind Follow-up duration: 1 y South Wales |
| Vogel, 1979 | Aspirin (1.5 g daily) on an average period of 22 months
versus Placebo | Double blind Follow-up duration: 1.75 y (mean) Germany | |
| AMIS, 1980 NCT00000491 | Aspirin (500 mg) 2x/d for at least 3 years versus Placebo | men and women who had had a documented myocardial infarction | Double blind Follow-up duration: > 3 y USA |
| GAMIS, 1980 | Aspirin (500 mg) 3x/d for 2 years versus Placebo | patients who had survived a myocardial infarction for 30-42 days | Double blind Follow-up duration: 2 y Germany, Austria, |
| PARIS, 1980 | Aspirin (324 mg) 3x/d versus Placebo | patients who had recovered from myocardial infarction | Double blind Follow-up duration: 41 mo USA, UK |
| JAMIS, 1999 | Aspirin (81 mg) 1x/d versus No antiplatelets | patients with AMI within 1 month from the onset of symptoms | Open Follow-up duration: 1.3 y (mean) Japan |
| WHS (diabetics sub group), 2005 | aspirin 100mg on alternate days versus placebo | healthy women 45 years of age or older - diabetics sub groups | double blind Follow-up duration: 10.1 y US |
| POPADAD aspirin, 2008 ISRCTN53295293 | aspirin 100mg daily versus placebo | patients with diabetes mellitus and asymptomatic peripheral arterial disease | double blind Follow-up duration: nov 1997 - jul 2001 Scotland |
| Women’s Health Study, 2005 | aspirin 100mg daily versus placebo | initially healthy women 45 years of age or older | Double blind Follow-up duration: 10.1 y mean (range 8.2 to 10.9 |
| SAPAT, 1992 | aspirin 75 mg daily versus placebo | patients with stable chronic angina pectoris | double blind Follow-up duration: 50 months Sweden |
| DAMAD, 1989 | aspirin alone (330 mg 3 times daily) or in combination with dipyridamole (75 mg 3 times daily) versus placebo | patients with early diabetic retinopathy | double blind Follow-up duration: 3 y |
| Schoop, 1983 | groupe 1 : Aspirine 990 mg / j
(pour mémoire : groupe 2 : Aspirine 990 mg / j + dipyridamole 225 mg/j) versus Placebo | AOMI stade non précisé | double blind Follow-up duration: <5 y |
| Hess, 1985 | groupe 1 : Aspirine 330 mg / j
(pour mémoire : groupe 2 : Aspirine 330 mg / j + dipyridamole 75 mg / j) versus Placebo | AOMI stade non précisé | single blind |
| aspirin + dipyridamol versus placebo | |||
| Hess (2), 1985 | Aspirine Dipyridamole 330 mg / j 225 mg / j versus Placebo | patients with occlusive arterial disease in the lower extremities | double blind |
| Schoop (2), 1983 | Aspirine Dipyridamole 990 mg / j 225 mg /j versus Placebo | AOMI stade non précisé | double blind |
| VA study, 1986 | Aspirine + Dipyridamole 975 mg / j 225 mg /j versus Placebo | non-insulin-dependent diabetic men with either a recent amputation for gangrene or active gangrene | double blind Follow-up duration: 46 months |
| atorvastatin versus placebo | |||
| SALTIRE, 2005 | atorvastatin 80mg daily versus placebo | patients with calcific aortic stenosis | double blind Follow-up duration: 25 mo (7-36) |
| ASCOT (diabetics sub group), 2003 | 10 mg atorvastatin versus placebo | hypertensive patients with no history of coronary heart disease (CHD) but at least three cardiovascular risk factors | |
| Deutsche Diabetes Dialyse Studie (4D), 2005 | atorvastatin 20mg daily versus matching placebo | patients with type 2 diabetes mellitus on maintenance hemodialysis | double blind Follow-up duration: 4 y (median) |
| ASPEN, 2006 | atorvastatin 10mg daily versus placebo | patients s with type 2 diabetes and LDL cholesterol levels below contemporary guideline targets | double blind Follow-up duration: 4y |
| SPARCL, 2006 NCT00147602 | atorvastatin 80mg daily versus placebo | patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 2.6 to 4.9 mmol per liter, and had no known coronary heart disease | double blind Follow-up duration: 4.9y (median) |
| Strey, 2005 | atorvastatin 40mg versus placebo | patients with stable, symptomatic heart failure (New York Heart Association Class II or III) and a left ventricular ejection fraction <40% | Follow-up duration: 6 weeks |
| ASCOT, 2003 | atorvastatin 10mg/d versus placebo | hypertensive patients aged 40-79 years with at least three other cardiovascular risk factors | double blind Follow-up duration: 3.3 years UK et Scandinavie |
| MIRACL, 2001 | Atorvastatin, 80 mg (early initiation) versus Placebo | unstable angina or non–Q-wave acute MI | Double blind Follow-up duration: 1 and 4 months Europe, North America, South Africa, and Australasia |
| ASPEN, 2006 | atorvastatin 10mg versus placebo | subjects with type 2 diabetes and LDL cholesterol levels below contemporaryguideline targets | double blind Follow-up duration: 4 year 14 countries |
| ASPEN (primary prevention sub group), 2006 | atorvastatin 10mg versus placebo | subjects with type 2 diabetes and LDL cholesterol levels below contemporary guideline targets; primary prevention subgroup | double blind Follow-up duration: 4 year 14 countries |
| macin, 2005 | atorvastatin 40 mg daily for 30 days versus placebo | patients admitted within 48 hours of onset of ACS with CRP levels > or =1.4 mg/dL | double-blind Follow-up duration: 30 days |
| Mohler III, 2003 | Atorvastatine: 10 mg/ jour ou 80 mg/ jour pendant 12 mois (groupes 1 et 2). versus placebo | Stade de la madie : II , stable pendant au moins 6 mois. | Double aveugle Follow-up duration: 1 an |
| CARDS, 2004 NCT00327418 | atorvastatin 10mg/d versus placebo | patients with type 2 diabetes without high concentrations of LDL-cholesterol and at least one of the following: retinopathy, albuminuria, current smoking, or hypertension. | double blind Follow-up duration: 3.9 years UK, Irelande |
| Mohler, 2003 | atorvastatin (10 mg per day) versus placebo | patients with intermittent claudication | double blind Follow-up duration: 12 months |
| Atorvastatin versus placebo | |||
| ASCOT (women subgroup) , 2003 | Atorvastatin 10 mg daily versus placebo | hypertensive patients (aged 40-79 years with at least three other cardiovascular risk factors) - subgroup of women | double-blind Follow-up duration: 3.3 y Europe |
| atorvastatin versus pravastatin | |||
| PROVE IT - TIMI 22, 2004 | 80 mg of atorvastatin daily (intensive therapy). versus 40 mg of pravastatin daily (standard therapy) | patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days | double blind Follow-up duration: 24 mo (18-36 mo) UK, US, AUstralia, Italy, France, Germany, Spain, Canada |
| atorvastatin versus usual care | |||
| Colivicchi, 2002 | Atorvastatin, 80 mg daily early initiation versus Usual care | unstable angina pectoris or non-Q-wave myocardial infarction | open Follow-up duration: 1, 3, and 6 months Italy |
| ESTABLISH, 2004 | Atorvastatin, 20 mg early initiation versus Usual care | patients with ACS undergoing emergency coronary angiography and percutaneous coronary intervention | open Follow-up duration: 1, 4, and 6 months Japan |
| GREACE, 2002 | atorvastatin 10-80 mg/d versus usual care | patients with established coronary heart disease | open Follow-up duration: 3 years mean |
| atorvastatin high dose versus angioplasty | |||
| AVERT, 1999 | atorvastatin 80 mg/d versus recommended percutaneous revascularization procedure(angioplasty) followed by usual care, whichcould include lipid-lowering treatment | patients referred for percutaneous revascularization, with stable coronary artery disease, relatively normal left ventricular function, asymptomatic or mild-to-moderate angina, and a serum level of low-density lipoprotein (LDL) cholesterol of at least 115 mg per deciliter (3.0 mmol per liter) | open Follow-up duration: 1.5 years US, Europe |
| atorvastatin high dose versus atorvastatin | |||
| TNT (diabetic sub group), 2006 | atorvastatin 80 mg daily versus atorvastatin 10 mg daily | patients with stable coronary heart disease | double blind Follow-up duration: 4.9 y |
| TNT, 2005 NCT00327691 | 80 mg of atorvastatin
daily versus 10 mg of atorvastatin daily | Chronic coronary artery disease LDL cholesterol < 3.4 mmol/L | double blind Follow-up duration: 4.9 years 14 countries |
| atorvastatin high dose versus lovastatin | |||
| Vascular basis, 2005 | atorvastatin (80 mg) with or without vitamin C and E versus low dose lovastatin (5 mg) | Chronic coronary artery disease | double blind Follow-up duration: 1 year |
| atorvastatin high dose versus pravastatin | |||
| PROVE-IT, 2004 | atorvastatin 80 mg daily versus Pravastatin 40 mg | acute myocardial infarction (with or without electrocardiographic evidence of ST-segment elevation) or highrisk unstable angina) in the preceding 10 days | double blind Follow-up duration: 2 years 8 countries |
| REVERSAL, 2004 | atorvastatin 80 mg daily versus Pravastatin(40 mg) | Chronic coronary artery disease | double blind Follow-up duration: 1.5 years |
| SAGE, 2007 | atorvastatin 80 mg daily versus pravastatin(40 mg) | Chronic coronary artery disease | double blind Follow-up duration: 1 years |
| atorvastatin high dose versus simvastatin | |||
| IDEAL, 2005 NCT00159835 | atorvastatin 80mg daily versus simvastatine 20mg/j | Men and women aged 80 years or younger with a history of a definite myocardial infarction and who qualified for statin therapy according to national guidelines | open Follow-up duration: 4.8 years Denmark, Finland, Iceland, Netherlands, Norway, Sweden |
| beta carotene versus placebo | |||
| ATBC 2nd prev subgroup (b carotene), 1998 | synthetic beta carotene 20 mg daily versus placebo | patients enroled in the ATBC trial and who had angina pectoris in the Rose chest pain questionnaire at baseline | double-blind Follow-up duration: 3.79 y Finland |
| ATBC beta carotene, 1994 | beta carotene 20mg four times daily versus placebo | male smokers 50 to 69 years of age from southwestern Finland | double-blind Follow-up duration: 6.1 median (range 5-8y) Southwestern Finland |
| CARET beta carotene, 1996 | combination of
30 mg of beta carotene per day and 25,000 IU of retinol
(vitamin A) in the form of retinyl palmitate per day versus placebo | smokers, former smokers, and workers exposed to asbestos | double-blind Follow-up duration: 4 y USA |
| NSCP (Green) beta carotene, 1999 | beta carotene 30mg four times daily versus placebo | residents of Nambour | double-blind Follow-up duration: 4.5 y Queensland, Australia |
| PHS beta carotene, 1996 | beta carotene 50 mg on alternate days versus placebo | male physicians, 40 to 84 years of age with no history of cancer (except nonmelanoma skin cancer), myocardial infarction, stroke, or transient cerebral ischemia | double-blind Follow-up duration: 12 y USA |
| SCP beta carotene, 1990 | beta carotene 50mg four times daily versus placebo | Age <85 years (most <65 years); previous non-melanoma skin cancer; 69% male | double-blind Follow-up duration: 4.02 years USA |
| WACS beta-caroten, 2007 NCT00000541 | beta carotene (Lurotin) 50 mg every two days
versus placebo | female health professionals at increased risk (40 years or older with a history of CVD or 3 or more CVD risk factors) | double blind Follow-up duration: 9.4 years |
| WHS beta carotene, 1999 NCT00000479 | beta carotene 50mg four times daily versus placebo | female health professionals, aged 45 years or older and without a history of cancer (except nonmelanoma skin cancer), coronary heart disease, or cerebrovascular disease | double-blind Follow-up duration: 2.1y (range 0 - 2.72y) USA |
| bezafibrate versus placebo | |||
| LEADER trial, 2000 | Bezafibrate: 400 mg/ jour pour les hommes avec créatininémie < 135 micromole/litre versus placebo de même aspect | Stade de la maladie : II. | Double aveugle Follow-up duration: 5 ans |
| BECAIT, 1996 | bezafibrate 200 mg three times daily versus placebo | dyslipidaemic male survivors of myocardial infarction who were younger than 45 years at the time of the event | double blind Follow-up duration: 5.0 years Sweden |
| BIP, 2000 | bezafibrate 400 mg/d versus placebo | patients with a previous myocardial infarction or stable angina, total cholesterol of 180 to 250 mg/dL, HDL-C < or =45 mg/dL, triglycerides < or =300 mg/dL, and low-density lipoprotein cholesterol < or =180 mg/dL | double blind Follow-up duration: 6.2 y Israel |
| LEADER, 2002 | bezafibrate 400 mg daily versus placebo | men with lower extremity arterial disease | double-blind Follow-up duration: 4.6y UK |
| SENDCAP, 1998 | bezafibrate 400 mg daily versus placebo | type 2 diabetic subjects without a history of clinical cardiovascular | double blind Follow-up duration: 3.0 years UK |
| cerivastatin versus placebo | |||
| Laufs, 2004 | cerivastatin 0.4 mg versus placebo | patients with heart failure NYHA II-III caused by non-ischemic dilated cardiomyopathy | double blind Follow-up duration: mean 20 weeks |
| cholestyramine versus control | |||
| STARS (cholestyramine), 1992 | cholestyramine versus diet | patients with angina or past myocardial infarction | Follow-up duration: 3 years |
| cholestyramine versus placebo | |||
| LRC, 1984 | cholestyramine 24 g daily versus placebo | asymptomatic middle-aged men with primary hypercholesterolemia (type II hyperlipoproteinemia) | double blind Follow-up duration: 7.4 years USA |
| NHLBI (Brensike), 1984 NCT00000594 | cholestyramine versus placebo | patients with Type II hyperlipoproteinemia and coronary artery disease | double blind Follow-up duration: 5.0 y |
| clofibrate versus placebo | |||
| Acheson, 1972 | clofibrate versus placebo | cerebral vascular disease | NA Follow-up duration: 6 years UK |
| Begg, 1971 | clofibrate versus placebo | peripheral arteriopathy | Follow-up duration: 3.5 y |
| CDP Clofibrate, 1975 | clofibrate 1.8 mg/d versus placebo | men, 30-64 y | double blind Follow-up duration: 6.2 years USA |
| Cullen, 1974 | clofibrate versus placebo | Follow-up duration: 2 years | |
| Hanefeld, 1991 | clofibric acid 1.6 g/day versus placebo | newly diagnosed middle-aged (30- to 55-yr-old) patients with non-insulin-dependent diabetes mellitus | double-blind Follow-up duration: 5 years Germany |
| Harrold, 1969 | clofibrate versus placebo | diabetic retinopathy | double-blind Follow-up duration: 1 years |
| Newcastle, 1971 | clofibrate 1.5-2 g daily versus placebo | Hommes et femmes < 65 ans | double blind Follow-up duration: 3.6 y UK |
| Scottish, 1971 | clofibrate 1.6-2 g daily versus placebo | Hommes et femmes, de 40 à 69 ans | double blind Follow-up duration: 3.4 years Scotland |
| VA Neurology Section, 1974 | clofibrate versus placebo | treatment of cerebrovascular disease | Follow-up duration: 1.8 years USA |
| WHO clofibrate, 1978 | clofibrate 1.6 g daily versus olive oil | primary prevention, Hommes, de 30 à 59 ans | double blind Follow-up duration: 5.3 years Scotland, Hungary, Czech Republic |
| clofibtate+niacin versus placebo | |||
| Carlson (Stockholm), 1977 | clofibrate, 1 g twice daily, and nicotinic acid 1 g three times daily versus control | survivors of a myocardial infarction below 70 years of age | open Follow-up duration: 5 years Sweden |
| clopidogrel versus aspirin | |||
| ASCET, NCT00222261 | clopidogrel 75 mg once daily for two years versus Aspirin 160 mg once daily for two years | patients with documented coronary heart disease and treated with aspirin | open |
| CAPRIE, 1996 | clopidogrel 75 mg once daily versus aspirin 325 mg once daily | patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease | Double blind Follow-up duration: mean 1.91 years 16 countries |
| CAPRIE (PAD subgroup), 1996 | Clopidogrel 75 mg versus Aspirine 325 mg | patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease | double blind Follow-up duration: 1.91 y |
| clopidogrel versus placebo (on top aspirin) | |||
| CHARISMA, 2006 NCT00050817 | clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) versus placebo plus low-dose aspirin | patients with either clinically evident cardiovascular disease or multiple risk factors | Double blind Follow-up duration: median 28 months 32 countries |
| cloricromene versus placebo | |||
| CRAMPS, 2000 | Cloricromène : 100 mg, 2 fois / jour / voie orale + aspirine : 160 mg / jour pendant 6 mois . versus placebo + aspirine: 160 mg/ jour pendant 6 mois. | Stade de la maladie : II, pendant 3.1 années d'ancienneté en moyenne dans les 2 groupes | double blind Follow-up duration: 6 months |
| colestipol versus placebo | |||
| Gross, 1973 | colestipol versus placebo | Follow-up duration: 1.0 years | |
| Gundersen, 1976 | colestipol 10g twice daily versus placebo | hypercholesterolemic patients | double-blind Follow-up duration: 0.8 years |
| Ruoff, 1978 | colestipol versus placebo | hypercholesterolemic patients | Follow-up duration: 3.2 years |
| Ryan, 1974 | colestipol15 g/day versus placebo | patients with hypercholesterolemia | Follow-up duration: 3.0 years |
| UCS (Dorr), 1978 | colestipol hydrochloride 32 mg/dl versus placebo | Hommes et femmes, > 18 ans | double blind Follow-up duration: 1.9 years |
| colestipol+clofibrate versus placebo | |||
| SCOR, 1990 | colestipol (15 to 30mg/d) + clofibrate (2g/d) versus diet | patients with primary hypercholesterolemia | Follow-up duration: 2.0 years |
| colestipol-niacin versus placebo | |||
| CLAS, 1987 | Colestipol + Niacin 30 g / j 3-12 g / j (titré sur chaque patient sur la base de la baisse de cholestérol sanguin) versus placebo: methyl cellulose | Patients coronariens avec antécédent de revascularisation chirurgicale coronarienne. | Non déterminable Follow-up duration: 2 ans |
| CLAS, 1987 | colestipol + niacin versus placebo | nonsmoking men aged 40 to 59 years with previous coronary bypass surgery | double blind Follow-up duration: 2 years |
| combination versus placebo | |||
| PHS II (multivitamin), 2012 NCT00270647 | Daily multivitamin versus placebo | male US physicians initially aged 50 years or older | double-blind Follow-up duration: 11.2y (median) USA |
| POPADAD (antioxydant), 2008 ISRCTN53295293 | antioxidant capsule containing (alpha-tocopherol 200 mg, ascorbic acid 100 mg, pyridoxine hydrochloride 25 mg, zinc sulphate 10 mg, nicotinamide 10 mg, lecithin 9.4 mg, and sodium selenite 0.8 mg) versus placebo | patients with diabetes mellitus and asymptomatic peripheral arterial disease | double blind Scotland |
| HATS, 2001 | antioxidant-therapy (vitamins) versus placebo | patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol | double-blind USA, Canada |
| MVP, 1997 | multivitamins (30,000 IU of beta carotene, 500 mg of vitamin C, and 700 IU of vitamin E) for four weeks before and six months after angioplasty versus placebo | patient undergoing angioplasty | double-blind Follow-up duration: 6 montsh Canada |
| HPS antioxidant, 2002 | antioxidant vitamin
supplementation (600 mg vitamin E, 250 mg vitamin C, and
20 mg -carotene daily) versus matching placebo | UK adults (aged 40–80) with coronary disease, other occlusive arterial disease, or diabetes | double-blind Follow-up duration: jul 1994 - may 1997 UK |
| PHS II beta carotene, 2003 NCT00270647 | 400 IU of vitamin E every other day and
500 mg of vitamin C daily versus placebo | US male physicians enrolled, aged 50 years or older | double-blind Follow-up duration: 8 years |
| SUVIMAX, 2005 | single daily capsule of combination of antioxydants: 120 mg of ascorbic acid, 30 mg of vitamin E, 6 mg of beta carotene, 100 ìg of selenium, and 20 mg of zinc versus matched placebo | women aged 35-60 years and men aged 45-60 years | double-blind Follow-up duration: 7.5 years France |
| WAVE (Waters), 2002 | 400 IU of vitamin E twice daily plus 500 mg of vitamin C twice daily versus placebo | postmenopausal women with at least one 15% to 75% coronary stenosis | double-blind Follow-up duration: 2.8 years US, Canada |
| combined estrogen and progestogen versus placebo | |||
| Schulman (NHLBI) (estrogen-progestogen), 2002 NCT00000601 | intravenous estrogen followed by oral conjugated estrogen
plus medroxyprogesterone for 21 days
versus placebo | Postmenopausal women with unstable angina | double blind Follow-up duration: 6 months USA, Brazil |
| EAGAR, 2006 NCT00000605 | estradiol +/-medroxyprogesterone versus placebo | Postmenopausal women who had undergone coronary artery bypass graft | double blind Follow-up duration: 33 months USA, Canada |
| ERA (estrogen plus medroxyprogesterone), 2000 NCT00000549 | estrogen plus medroxyprogesterone acetate ( 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day)
versus placebo | Postmenopausal women with established coronary atherosclerosis | double-blind Follow-up duration: 3.6y USA |
| EVTET, 2000 | 2 mg estradiol plus 1 mg norethisterone acetate, 1 tablet daily versus placebo | postmenopausal women younger than 70 years who had suffered previous DVT or PE | double-blind Follow-up duration: 24 months Norway |
| Hall, 1998 | transdermal 17 beta-estradiol at a dose of 50 micrograms per 24 h alone for 18 days followed by 10 days of combined treatment with medroxyprogesterone acetate (MPA) 5 mg orally versus placebo | postmenopausal women with coronary artery disease aged 44–75 years | double-blind Follow-up duration: 1 y Sweden |
| HERS, 1998 NCT00319566 | Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily versus placebo | women with coronary disease, younger than 80 years, and postmenopausal with an intact uterus | double-blind Follow-up duration: 4.1 y US |
| WAVE, 2002 NCT00000555 | 0.625 mg/d of conjugated equine estrogen (plus 2.5 mg/d of medroxyprogesterone acetate for women who had not had a hysterectomy) versus placebo | Postmenopausal women, up to age 86, with angiographically documented coronary artery disease of at least 15 percent, but no more than 75 percent occlusion | double blind Follow-up duration: 2.8 y United States, Canada |
| WELL-HART (estrogen-progestin), 2003 NCT00000559 | 17 beta-estradiol plus sequentially administered
medroxyprogesterone acetate versus placebo | Postmenopausal women with angiographically-documented coronary disease | double blind Follow-up duration: 3.3 y USA |
| WHI, 2002 | conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet versus placebo | postmenopausal women aged 50-79 years with an intact uterus at baseline | double-blind Follow-up duration: 5.2 y USA |
| WHISP, 2006 | oral oestradiol-17beta 1 mg plus norethisterone acetate 0.5 mg daily versus placebo | post-menopausal women >55 years were enrolled between 2 and 28 days after an acute coronary syndrome | double-blind Follow-up duration: 1 y UK |
| WISDOM, 2007 ISRCTN63718836 | combined estrogen and progestogen versus placebo | postmenopausal women aged 50-69 | double-blind Follow-up duration: 11.9 months UK, Australia, New Zealand |
| coumarin congeners versus placebo | |||
| Sixty Plus Reinfarction, 1980 | acenocoumarin orphenprocoumon versus placebos | elderly patients who had been on anticoagulants ever since their primary myocardial infarction | double-blind Follow-up duration: 2 years |
| dalcetrapib versus placebo | |||
| dal-VESSEL, 2011 | dalcetrapib 600 mg daily versus placebo | men and women with coronary heart disease or coronary heart disease risk equivalents with HDL-cholesterol levels <50 mg/dL | double-blind Follow-up duration: 12 weeks |
| dal-OUTCOMES, 2012 NCT00658515 | dalcetrapib 600 mg daily beginning 4 to 12 weeks after an index ACS event versus placebo | patients with recent acute coronary syndrome | double-blind Follow-up duration: 31 montsh (median) 27 countries |
| darapladib versus placebo | |||
| SOLID-TIMI 52, NCT01000727 | versus | ||
| dicoumarol versus no anticoagulant | |||
| Apenstrom and Korsan-Bengtsen, 1964 | versus | ||
| diet versus control | |||
| NORDIET, | healthy Nordic diet versus control diet (subjects’ usualWestern diet) | mildly hypercholesterolaemic subjects | Sweden |
| BARON, | versus | ||
| HPT, | versus | ||
| Kumanyika, | versus | ||
| TAIM, | versus | ||
| DISH, | versus | ||
| Burr (DART 2), 2003 | dietary advice (to eat more oily fish) versus No such dietary advice or capsules | men being treated for angina | open Follow-up duration: 36-108 months UK |
| Burr (DART), 1989 | dietary advice (to eat more oily fish) versus No such dietary advice or capsulesish)ag | post-MI | open Follow-up duration: 24 months UK |
| Mate-Jimenez, 1991 | diet advice versus no advice | people with inactive Crohn’s disease | open with blind assessment Follow-up duration: 24months Spain |
| diet versus usual diet | |||
| Black, 1994 | diet with 20 percent of total caloric intake as fat versus usual diet | patients with nonmelanoma skin cancer | open Follow-up duration: 2.0 years |
| DART (Burr), 1989 | diet advice versus usual diet | men who had recovered from MI | open, blind assessment Follow-up duration: 2 years |
| Finnish Mental Hospital (Miettinen), 1985 | cholesterol-lowering diet (low in saturated fats and cholesterol and relatively high in polyunsaturated fats) versus usual diet | middle-aged institionalized women without CHD | open, blind assessment Follow-up duration: 6.0 years Finland |
| Finnish Mental Hospital (Turpeinen), 1979 | cholesterol-lowering diet (low in saturated fats and cholesterol and relatively high in polyunsaturated fats) versus usual diet | middle-aged institutionalized men without CHD | open, blind assessment Follow-up duration: 6.0 years Finland |
| Goteborg, 1986 | multifactorial intervention programme versus no intervention | men, 47-55 years old at entry | open Follow-up duration: 10 years Sweden |
| Göteborg (Wilhelmsen), 1986 | multifactorial intervention programme versus usual care | men, 47-55 years old at entry | open Follow-up duration: 10.0 years |
| Hjermann, 1981 | diet versus usual diet | healthy, normotensive men at high risk of coronary heart disease | open Follow-up duration: 6.5 years Sweden |
| Kallio, 1979 | diet (multifactorial intervention programme) versus usual diet | patients below 65 years who had an acute myocardial infarction | open Follow-up duration: 3.0 years |
| Los Angeles VA (Dayton), 1969 | diet versus usual diet | men in domicilary care, age>55, with or without CHD | double blind Follow-up duration: 8.0 y USA |
| Minnesota coronary survey (Frantz), 1975 | cholesterol lowering diet versus control diet | Adult residents ofmental hospitals; no illness restrictions, no cholesterol concentration requirements | double-blind Follow-up duration: 1.1 y (max 4.5y) USA |
| MRC low fat, 1965 | versus | open Follow-up duration: 3 y | |
| MRC Soya, 1968 | Régime pauvre en graisses saturées + 85 g/j d'huile de soja versus usual diet | ambulatory men with recent MI | open, blind assessment Follow-up duration: 3.5 y |
| MRFIT, 1982 | multifactor intervention program versus usual diet | high-risk men aged 35 to 57 years | open Follow-up duration: 6.5 y |
| Ornish, 1990 | low-fat vegetarian diet, stopping smoking, stress management training, and moderate exercise versus usual-care | Patients with angiographically documented coronary artery disease | open Follow-up duration: 1.0 y USA |
| Oslo Diet Heart Study (Leren), 1966 | diet versus usual care | middle-aged ambulatory men with prior MI | open, blind assessment Follow-up duration: 5 y (11y) |
| Rose, 1965 | Régime restreint en graisses + 80 g/j huile de maïs versus usual diet | men, <70 years | open Follow-up duration: 1.2 years |
| Singh, 1992 | strict diet versus usual diet | patients with suspected acute myocardial infarction | open Follow-up duration: 2.0 years |
| STARS (St Thomas, diet), 1992 | dietary advice versus usual diet | patients with angina or past myocardial infarction | open, blind assessment Follow-up duration: 3.0 years |
| Veterans Ad. (Dayton), 1969 | cholesterol lowering diet versus usual diet | men in domicilary care, age>55, with or without CHD | double blind Follow-up duration: 3.6 and 8 y USA |
| WHI low fat, 2005 NCT00000611 | dietary modification intervention to promote dietary change with the goals of reducing intake of total fat to 20% of energy and increasing consumption of vegetables and fruit to at least 5 servings daily and grains to at least 6 servings daily versus usual diet | postmenopausal women, aged 50 to 79 years, without prior breast cancer | open Follow-up duration: 8.1y mean US |
| WHO Collaborative, 1986 | multifactorial prevention versus usual diet | middle-aged men | open Follow-up duration: 5.5 years Belgium, Italy, Poland, UK |
| Woodhill, 1966 | diet versus usual diet | men, 30-59 years | open Follow-up duration: < 7 years |
| dipyridamol versus control | |||
| Atlanta (Sbar), 1967 | dipyridamole 150mg daily versus placebo | patients with angina pectoris | double-blind Follow-up duration: 6 months |
| Wirecki, 1967 | dipyridamole 150mg daily versus placebo | patients with angina pectoris | double blind Follow-up duration: 7 months |
| Becker, 1967 | dipyridamole 225mg daily versus placebo | double-blind Follow-up duration: 5 months | |
| dipyridamol versus placebo | |||
| Kinsella, 1962 | dipyridamole 37.5 mg and 100mg daily versus placebo | double-blind Follow-up duration: 0.5 months | |
| Leiberman, 1964 | dipyridamole 100mg daily versus placebo | double blind Follow-up duration: >3 months | |
| Zion, 1961 | Dipyridamole 37.5mg versus placebo | patients with angina pectoris | double-blind Follow-up duration: 0.5 months |
| Dewar, 1961 | Dipyridamole 100mg daily versus placebo | patients with angina pectoris | double-blind Follow-up duration: 0.5 months |
| Neumann, 1964 | dipyridamole 150mg daily versus placebo | elderly with precordial pain | double-blind Follow-up duration: 1.5 months |
| Foulds, 1960 | Dipyridamole 200mg daily versus placebo | patients with angina pectoris | double-blind Follow-up duration: 1 months |
| Igloe, 1970 | Dipyridamole 200mg daily versus placebo | patients with angina pectoris | double blind Follow-up duration: 2-7 months |
| dipyridamol + aspirin versus aspirin | |||
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Aspirin (324 mg) 3x/d | patuents who had recovered from myocardial infarction | Double blind Follow-up duration: 41 months USA and GB |
| dipyridamol + aspirin versus placebo | |||
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Placebo | patients who had recovered from myocardial infarction | Double blind Follow-up duration: 41 months (mean) USA and UK |
| PARIS-II, 1986 | Aspirin (330 mg) + dipyridamole (75 mg) 3x/d versus Placebo | patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously | Double blind Follow-up duration: 23.4 months USA and UK |
| Efamol marine versus placebo | |||
| Veale, 1994 | Efamol marine capsules, 12/d (0.4g/d EPA + DHA plus 0.5g/d gamma-linoleic acid (notomega-3))TP versus placebo (capsules containing liquid paraffin and vitamin E, 12/d, appeared identical) | people with chronic stable plaque psoriasis and inflammatory arthritis | double blind Follow-up duration: 9 months UK |
| Esapent versus placebo | |||
| Maresta, 2002 | Esapent capsules, 6/d for 2 mo, then 3/d (5.1g/d EPA + DHA initially, later 2.6g/d) versus placebo (identical olive oil capsules, 6/d for 2 mo, then 3/d) | undergoing planned PTCAB | double-blind Follow-up duration: 7 months Italy |
| Sirtori, 1998 | Esapent fish oil capsules 3/d for first 2 mo, 2/d after that (2.6g/dEPA + DHA initially, then 1.8g/d) versus placebo (olive oil capsules 3/d for first 2 mo, 2/d after that) | people with raised triglycerides plus glucose intolerance, non-insulindependant diabetes or hypertension | double blind Follow-up duration: 6 months Italy |
| Eskisol versus placebo | |||
| Rossing, 1996 | Eskisol fish oil emulsion 21 ml/d (4.6g EPA +DHA) versus placebo (olive oil emulsion 21 ml/d) | people with insulin dependant diabetes, diabetic nephropathy and normalBP | double blind Follow-up duration: 12 months Denmark |
| estrogen versus placebo | |||
| EPAT, 2001 | micronized 17beta-estradiol (1 mg/d) versus placebo | postmenopausal women 45 years of age or older without preexisting cardiovascular disease and with low-density lipoprotein cholesterol levels of 3.37 mmol/L or greater (>/=130 mg/dL) | double-blind Follow-up duration: 2 y USA |
| ERA (estrogen alone ), 2000 NCT00000549 | estrogen alone (0.625 mg of conjugated estrogen per day) versus placebo | Postmenopausal women with established coronary atherosclerosis | double-blind Follow-up duration: 3.6y USA |
| ESPRIT, 2002 | oestradiol valerate 2 mg daily versus placebo | postmenopausal women, age 50-69 years who had survived a first myocardial infarction | double-blind Follow-up duration: 24 months England and Wales |
| Schulman (NHLBI) (estrogen alone), 2002 NCT00000601 | intravenous followed by oral
conjugated estrogen for 21 days, intravenous estrogen followed by oral conjugated estrogen
plus medroxyprogesterone for 21 days versus placebo | Postmenopausal women with unstable angina | double blind Follow-up duration: 6 months USA, Brazil |
| WELL-HART (estrogen alone), 2003 NCT00000559 | micronized 17beta-estradiol alone versus placebo | Postmenopausal women with angiographically-documented coronary disease | double blind Follow-up duration: 3.3 y USA |
| WEST, 2001 | estrogen therapy (1 mg of estradiol-17beta per day) versus placebo | postmenopausal women who had recently had an ischemic stroke or transient ischemic attack | double-blind Follow-up duration: 2.8 y USA |
| CDP estrogen 2.5, 1975 | estrogen 2.5 mg daily versus placebo | Follow-up duration: 4.7 years | |
| CDP estrogen 5, 1975 | estrogen 5.0 mg daily versus placebo | Follow-up duration: 1.5 years | |
| Marmorstein, 1962 | estrogen versus placebo | Follow-up duration: 5.0 y | |
| Stamler, 1963 | estrogen versus placebo | Follow-up duration: 5.0 years | |
| VA Neurology Section (estrogen), 1966 | estrogen versus placebo | Follow-up duration: 1.4 years | |
| estrogen or thyroxine versus placebo | |||
| VA drugs (Estrogen or thyroxine), 1968 | estrogen or thyroxine versus placebo | Follow-up duration: 3.2 years | |
| etofibrate versus placebo | |||
| Emmerich, 2009 | etofibrate 1g/j versus placebo | patients with type 2 diabetes mellitus and concomitant diabetic retinopathy | double-blind Follow-up duration: 12 months Germany |
| evacetrapib versus placebo | |||
| ACCELERATE, 2017 NCT01687998 | evacetrapib at adose of 130 mg versus placebo | Patients at a High-Risk for Vascular Outcomes who had at least one of the following conditions: an acutecoronary syndrome within the previous 30 to 365 days, cerebrovascular atheroscleroticdisease, peripheral vascular arterial disease, or diabetes mellitus with coronaryartery disease | double-blind 37 countries |
| evolocumab versus ezetimibe alone | |||
| GAUSS 2, NCT01763905 | evolocumab 140 mg every two weeks (Q2W) or evolocumab 420 mg once monthly (QM) versus ezetimibe 10 mg | patients with statin intolerance | |
| evolocumab versus placebo | |||
| GAUSS 1, 2012 NCT01375764 | versus | statin-intolerant patients | |
| evolocumab versus placebo (on top statins) | |||
| DESCARTES, 2014 NCT01516879 | evolocumab (420 mg) every 4 weeks versus placebo | Follow-up duration: 52 weeks | |
| FOURIER, 2017 NCT01764633 | evolocumab (either 140 mg every 2 weeks or 420 mg monthly) versus placebo | patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy | double-blind Follow-up duration: 2.2 years |
| LAPLACE 2, 2014 NCT01763866 | evolucumab + statin versus placebo + statin | ||
| LAPLACE-TIMI 57, NCT01380730 | subcutaneous injections of AMG 145 70 mg, 105 mg, or 140 mg, versus placebo | ||
| RUTHERFORD-1, NCT01375751 | AMG 145 350 mg, AMG 145 420 mg versus placebo | heterozygous familial hypercholesterolemia patients | |
| RUTHERFORD-2, 2015 NCT01763918 | subcutaneous evolocumab 140 mg every 2 weeks, evolocumab 420 mg monthly versus placebo | heterozygous familial hypercholesterolaemia | |
| ezetimibe versus niacin | |||
| ARBITER-HALTS 6, 2010 | addition of ezetimibe (10 mg/daily) to statin therapy versus extended-release niacin 2000 mg/daily | patients at high risk for vascular disease but with LDL-cholesterol levels <100 mg/dL and moderately low HDL-cholesterol levels (<50 mg/dL) | open Follow-up duration: 14 months |
| ezetimibe versus placebo (on top statins) | |||
| IMPROVE-IT, 2014 NCT00202878 | 10 mg/day of ezetimibe and 40 mg/day of simvastatin versus simvastatin 40 mg/day | subjects with stabilized high-risk acute coronary syndrome | double blind Follow-up duration: 5.68 years 39 countries |
| Enhance, 2008 | ezetimibe 10mg + simvastatin daily versus simvastatin 80mg daily | patients with familial hypercholesterolemia | double blind Follow-up duration: 24 months |
| ezetimibe+simvastatin versus placebo | |||
| SEAS, 2008 NCT00092677 | simvastatin 40mg plus ezetimibe 10 mg daily versus placebo | patients with mild-tomoderate, asymptomatic aortic stenosis | double blind Follow-up duration: 52.2 mo Europe |
| SHARP, 2010 NCT00125593 | Simvastatin 20mg/Ezetimibe 10mg versus placebo | patients with established chronic kidney disease (dialysis or pre-dialysis) | double-blind Follow-up duration: 4.9 years 20 countries |
| fenofibrate versus placebo | |||
| FIELD, 2005 ISRCTN64783481 | fenofibrate 200 mg daily versus placebo | aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry | Follow-up duration: 5y |
| DAIS, 2001 | fenofibrate 200 mg/day versus placebo | men and women with type 2 diabetes and coronary atherosclerosis | double-blind Follow-up duration: 3.3 years Canada, Finland, France, Sweden |
| FIELD, 2005 ISRCTN64783481 | fenofibrate 200mg/d versus Placebo | participants aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry | double blind Follow-up duration: 5 years Australia, New Zealand, Finland |
| fenofibrate versus placebo (on top simvastatine) | |||
| ACCORD lipid, 2010 NCT00000620 | fenofibrate on top simvastatin versus placebo (on top simvastatine) | high-risk patients with type 2 diabetes | double-blind Follow-up duration: 4.7y United States and Canada |
| fish oil versus control | |||
| Bemelmans, 2002 | a-lin rich margarine (80% fat of which 15% was a-lin) versus linoleic rich margarine (80% fat of which 0.3% was a-lin), identical in taste and packaging | patients with multiple cardiovascular risk factors (10 yr IHD risk ~20%) | double-blind Follow-up duration: 24 months the Netherlands |
| Brox, 2001 | seal oil - 15 ml/d (2.6g EPA + DHA) versus no supplement | dyslipidaemia | open with blind assessment |
| Franzen, 1993 | fish oil capsules, 9g/d (1.8g EPA + 1.4g DHA daily) versus olive oil capsules | people with angiographically determined CHDg | double-blind Follow-up duration: 12 months |
| Katan, 1997 | Fish oil capsules, all took 9 per day (1.1g omega-3 fats low dose, 2.2g medium dose, 3.3g high dose per day) versus 9 olive and palm oil capsules (0g omega-3 fats per day)j | healthy monks | NA Follow-up duration: 12 months The Netherland |
| Malaguarnera, 1999 | EPA + DHA daily (3g/d EPA + DHA) plus IFNa subcutaneously versus IFNa subcutaneously only | chronic hepatitis with ALT =2x normal limit for =12 mo | open Follow-up duration: 6 months Italy |
| Shimizu, 1995 | EPA-ethyl capsules 3/d (0.9g/d EPA) versus no treatment | people with non-insulin dependant diabetes | open Follow-up duration: 12 months Japan |
| Terano, 1999 | DHA capsules, 6/d (4.3g/d DHA) versus no treatment | dementia of CVD | open with blind assessment Follow-up duration: 12 months japan |
| fish oil versus placebo | |||
| Almallah, 1998 | fish oil extract, 15 ml/d (5.6g EPA + DHA) versus placebo (sunflower oil, 15 ml/d) | people with distal procto-collitis (ulcerative colitis) | single blind and outcome ass. Follow-up duration: 6 months UK |
| Borchgrevink, 1966 | linseed oil 10 ml/d initially, later raised to 20 or 30 ml/d (4.5g/d a-lin, later 9 or 13.5 g/d) versus placebo (corn oil, 10 ml/d initially, later raised to 20 or 30 ml/d) | men with impending or recent myocardial infarctionage/p | double-blind Follow-up duration: mean 10 months (range 3-16 mo) Norway |
| Dry, 1991 | Liparmonyl (1g/d EPA + DHA) versus placebo | people with asthma | double blind Follow-up duration: 12 months France |
| Geusens, 1994 | high and ow dose fish oil capsules versus placebo (olive oil capsules, 6/d) | people with active rheumatoid arthritis on NSAIDs or DMARDs | double blind Follow-up duration: 12 months Belgium |
| Leaf, 1994 | fish oil concentrate capsules 10x1 g/d (6.9g/d EPA + DHA) versus placebo (corn oil capsules 10x1 g/d with 0.4% fish oil to maintain blinding (0.003g/d EPA + DHA)) | people undergoing angioplasty | double blind Follow-up duration: 6 months US |
| Loeschke, 1996 | fish oil capsules 6x1 g/d (5.1g/d omega-3 fats), with orange flavour versus placebo (maize oil capsules 6x1 g/d with orange flavour) | people with ulcerative colitis, in remission | double-blind Follow-up duration: 24 months Germany |
| Lorenz-Meyer, 1996 | ethyl ester fish oil concentrate capsules 6x1 g daily (5.1g/d EPA + DHA) versus placebo (corn oil capsules 6x1 g daily) | people with Crohn’s disease in remission | double blind Follow-up duration: 12 months |
| Sacks (TOHP 1), 1994 NCT00000528 | fish oil versus placebo | double blind | double-blind |
| von Schacky, 1999 | concentrated fish oil capsules, 6/d for first 3 mo, 3/d for rest of study (4g/d EPA +DHA + DPA+ a-lin for first 3 mo, then 2g/d) versus placebo (capsules containing fat which replicated the fat composition of the average European diet, 6/d forfirst 3 mo, 3/d for rest of study, opaque soft gelatine capsules identical to fish capsules) | people with angiographically proven coronary artery disease | double blind Follow-up duration: 24 months Germany |
| fluvastatin versus placebo | |||
| LIPS (diabetic sub group), 2002 | fluvastatin versus placebo | patients (aged 18-80 years) with stable or unstable angina or silent ischemia following successful completion of their first PCI who had baseline total cholesterol levels between 135 and 270 mg/dL | double blind Follow-up duration: 3.9y |
| ALERT (diabetic sub group), 2003 | fluvastatin versus placebo | renal transplant recipients with total cholesterol 4·0–9·0 mmol/L | double blind |
| ALERT, 2003 | fluvastatin versus placebo | renal transplant recipients with total cholesterol 4·0–9·0 mmol/L. | double blind Follow-up duration: 5.1 years |
| FLARE (elderly subgroup), 1999 | Fluvastatin 80mg versus | CAD requiring PCI, subgroup of age 65-80 y | double blind Follow-up duration: 0.8y |
| LIPS (sub groups), 2002 | Fluvastatin, 80 mg versus Placebo | patients with unstable angina and successful first percutaneous coronary intervention | double blind Follow-up duration: 1, 4, and 6 months Europe, Canada, and Brazil |
| ALERT, 2003 | fluvastatin 40 mg daily versus placebo | renal transplant recipients with total cholesterol 4.0-9.0 mmol/L | double-blind Follow-up duration: 5.1 years Belgium, Denmark, Finland, Germany, Norway, |
| LIPS (elderly subgroup), 2002 | Fluvastatin 80mg versus | CAD requiring PCI, subgroup of age 65-80 y | double blind Follow-up duration: 3.9y |
| FLORIDA, 2002 | Fluvastatin, 80 mg (early initiation) versus Placebo | patients with an AMI and total cholesterol of <6.5 mmol.l | double blind Follow-up duration: 1, 4, and 6 months The Netherlands |
| BCAPS, 2001 | fluvastatin 40 mg once daily versus placebo | subjects who had carotid plaque but no symptoms of carotid artery disease | double-blind Follow-up duration: 3.0 years Sweden |
| FLARE, 1999 | fluvastatin 40 mg twice daily versus placebo | successful coronary balloon angioplasty | double blind Follow-up duration: 40 weeks |
| HYRIM, 2005 | fluvastatin 40 mg daily versus placebo | drug-treated hypertensive men aged 40-74 years with total cholesterol 4.5-8.0 mmol/L, triglycerides <4.5 mmol/L, body mass index 25-35 kg/m2, and a sedentary lifestyle | double blind Follow-up duration: 4 year Norway |
| LCAS, 1997 | fluvastatin 20 mg twice daily versus placebo | men and women aged 35 to 75 years with angiographic CHD and mean low-density lipoprotein (LDL) cholesterol of 115 to 190 mg/dl despite diet | double-blind Follow-up duration: 2.5 years |
| LIPS, 2002 | fluvastatin, 80 mg/d versus placebo | patients (aged 18-80 years) with stable or unstable angina or silent ischemia following successful completion of their first PCI who had baseline total cholesterol levels between 3.5-7.0 mmol/L and with fasting triglyceride levels of less than 4.5 mmol/L | double blind Follow-up duration: 3.9 years Europe, Canada, and Brazil |
| Riegger et al., 1999 | fluvastatin 40 mg (o.a.d. or b.i.d.) versus placebo | hyperlipidaemic patients with symptomatic, clinically-diagnosed (exercise-ECG) coronary heart disease | double blind Follow-up duration: 1.0 years |
| folic acid versus control | |||
| FOLARDA (Liem), 2004 | folic acid 5 mg per day for 1 year versus usual care | patients with acute MI and total cholesterol >6.5 mmol/l | open Follow-up duration: 1 year The Netherlands |
| GOES (Liem), 2003 | folic acid 0.5 mg per day versus usual care | patients with stable coronary artery disease | open Follow-up duration: 24 months The Netherlands |
| folic acid versus placebo | |||
| CSPPT, 2015 NCT00794885 | enalapril 10 mg / folic acid 0.8 mg daily versus Enalapril maleate 10 mg daily | patients with primary hypertension | double-blind China |
| CHAOS-2, 2002 | folic acid 5 mg per day (for 2 years) versus placebo | patient with CHD | double blind Follow-up duration: 1.7 y |
| folic acid, B12 versus control | |||
| NORVIT (folic acid + B12) (Bonaa), 2006 NCT00266487 | folic acid 0.8mg and B12 0.4 mg daily
versus no folic acid and B12 | men and women who had had an acute myocardial infarction within seven days before | double-blind Follow-up duration: 36 months Norway |
| folic acid, B12 versus placebo | |||
| WENBIT (folic ac,B12), 2008 NCT00354081 | folic acid 0.8mg, vit B12 0.4mg daily
versus placebo | adult participants undergoing coronary angiography | double blind Follow-up duration: 38.4 mo Norway |
| SEARCH, 2007 NCT00124072 | folic acid 2mg/d + vitamin B12 1mg/d versus placebo | patients survivors of myocardial infarction | double blind Follow-up duration: 7 years UK |
| folic acid, vit B12 and vit B6 versus control | |||
| NORVIT (folic acid, B12 and vit B6) (Bonaa), 2006 NCT00266487 | 0.8 mg of folic acid, 0.4 mg of vitamin B12, and 40 mg of vitamin B6 versus placebo | men and women who had had an acute myocardial infarction within seven days | double-blind Follow-up duration: 36 months Norway |
| folic acid, vit B12 and vit B6 versus placebo | |||
| VITATOPS, 2010 NCT00097669ÐX& | folic acid and vitamins B12 and B6 in a single tablet versus placebo | patients with recent stroke or TIA (within the past seven months) | double-blind Follow-up duration: 3.4 y 20 countries |
| SU.FOL.OM3, ISRCTN41926726 | supplementation with natural foLate, vitamin B6 and B12 versus placebo | patients with coronary or cerebral event within the previous 12 months | double-blind France |
| HOPE-2 (Lonn), 2006 NCT00106886 | folic acid, 2.5 mg, vitamin B6,50 mg and vitamin B12, 1mg versus placebo | patients 55 years of age or older who had vascular disease or diabetes and additional risk factors for atherosclerosis | double blind Follow-up duration: Jan 2000 - dec 2000 13 countries |
| WAFACS, 2008 NCT00000541 | folic acid 2.5mg, vitamin B6 50mg, and vitamin B12 1mg daily versus placebo | women aged 42 years or older, with either a history of CVD or 3 or more coronary risk factors | double blind Follow-up duration: 7.3 y US |
| gemfibrozil versus placebo | |||
| HHS (diabetic sub group), 1987 | gemfibrozil 600mg twice daily versus placebo | asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter | double blind |
| VA-HIT (diabetic sub group), 1999 | gemfibrozil 1200 mg per day versus placebo | men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less. | double blind Follow-up duration: 5.1 y |
| Helsinki (HHS), 1987 | gemfibrozil 1,2 g/d versus placebo | asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter [5.2 mmol per liter] | double blind Follow-up duration: 5 years Finland |
| HHS (Frick)(secondary prev subgroup), 1993 | gemfibrozil 600 mg twice daily versus placebo | individuals who exhibited symptoms and signs of possible coronary heart disease | double blind Follow-up duration: 5.0 years Sweden |
| LOCAT, 1997 | gemfibrozil 1200 mg/d versus placebo | post-coronary bypass men, who had an HDL cholesterol concentration < or = 1.1 mmol/L and LDL cholesterol < or = 4.5 mmol/L | double blind Follow-up duration: 32 months Germany |
| VA-HIT, 1999 NCT00283335 | gemfibrozil 1.2g daily versus placebo | men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less | double blind Follow-up duration: 5.1 years USA |
| HiEPA versus placebo | |||
| Hawthorne, 1992 | HiEPA oil, 10 ml x 2/d (5.6g/d EPA + DHA) versus placebo (olive oil, 10 ml x 2/d (0g/d EPA + DHA)) | people with ulcerative colitis | double blind Follow-up duration: 12 months UK |
| high dose - folic acid, vit B12 and vit B6 versus low dose - folic acid, vit B12 and vit B6 | |||
| VISP (Toole), 2004 | high-dose of folic acid, pyridoxine (vitamin B6),
and cobalamin (vitamin B12) versus low-dose of folic acid, pyridoxine (vitamin B6), and cobalamin (vitamin B12) | adults with nondisabling cerebral infarction | double blind Follow-up duration: 2 y United States, Canada, Scotland |
| hormonal replacement therapy versus placebo | |||
| PEPI, 1995 NCT00000466 | estrogen replacement therapy versus placebo | Postmenopausal women, ages 45 to 64 | double blind Follow-up duration: 3 years USA |
| intensive lipid-lowering therapy versus diet | |||
| FATS, 1990 NCT00000512 | intensive lipid-lowering therapy with various drugs versus placebo | men no more than 62 years of age who had apolipoprotein B levels greater than or equal to 125 mg per deciliter, documented coronary artery disease, and a family history of vascular disease | open Follow-up duration: 2.5 years Japan |
| ketanserine versus placebo | |||
| Thulesius, 1987 | Ketanserin 60 mg / j pdt 2 semaines 120 mg / j ensuite versus Placebo | patients with intermittent claudication (stade II) | double blind Follow-up duration: 6 months |
| Walden, 1991 | Ketanserin 60 mg / j pdt 1 mois 120 mg / j ensuite versus Placebo | patients with intermittent claudication (stade II) | double blind Follow-up duration: 15 months |
| PACK, 1996 | Ketanserin 40 mg / j pdt 1 mois 80 mg / j ensuite versus Placebo | patients over 40 years old who had had documented intermittent claudication for at least two months and in whom the ratio of systolic blood pressure in the ankle to that in the arm was less than or equal to 0.85 in both arteries of at least one foot | double blind Follow-up duration: 1 y |
| lovastatin versus placebo | |||
| ACAPS, 1994 NCT00000469 | lovastatin 20mg daily versus placebo | men and women, 40 to 79 years old, with early carotid atherosclerosis and moderately elevated LDL cholesterol. | double blind Follow-up duration: 2.8 years USA |
| AFCAPS/TexCAPS (diabetic sub group), 1998 | lovastatin versus placebo | men and women without clinically evident atherosclerotic cardiovascular disease with average total cholesterol (TC) and LDL-C levels and below-average high-density lipoprotein cholesterol (HDL-C) levels | double blind |
| AFCAPS/TexCAPS, 1998 | lovastatin 20-40 mg/d versus placebo | men and women without clinically evident atherosclerotic cardiovascular disease with average total cholesterol (TC) and LDL-C levels and below-average high-density lipoprotein cholesterol (HDL-C) levels | double blind Follow-up duration: 5.2 years USA |
| CCAIT, 1994 | lovastatin begun at 20 mg/d and titrated to 40 and 80 mg during the first 16 weeks to attain a fasting low-density lipoprotein (LDL) cholesterol < or = 130 mg/dL versus placebo | patients with diffuse but not necessarily severe coronary atherosclerosis documented on a recent arteriogram and with fasting serum cholesterol between 220 and 300 mg/dL | double-blind Follow-up duration: 2 years Canada |
| CRISP 20mg, 1994 NCT00000477 | lovastatin 20mg daily versus placebo | elderly (mean 71y) with low-density lipoprotein cholesterol levels greater than 4.1 and less than 5.7 mmol/L | double blind Follow-up duration: 1 years |
| CRISP 40mg, 1994 NCT00000477 | lovastatin 40 mg daily versus placebo | elderly (mean 71y) with low-density lipoprotein cholesterol levels greater than 4.1 and less than 5.7 mmol/L | double blind Follow-up duration: 1 years |
| Excel, 1991 | lovastatin (20 mg once daily, 40 mg once daily, 20 mg twice daily, or 40 mg twice daily) versus placebo | patients with moderate hypercholesterolemia | double blind Follow-up duration: 0.9 years |
| MARS, 1993 NCT00116870 | lovastatin 80 mg/day versus placebo | patients, 37 to 67 years old, with total cholesterol ranging from 4.92 to 7.64 mmol/L (190 to 295 mg/dL) and angiographically defined coronary artery disease | double blind Follow-up duration: 2.0y |
| Weintraub, 1994 | lovastatin 40 mg orally twice daily versus placebo | patients undergoing PTCA | double blind Follow-up duration: 0.5 years |
| Lovastatin versus placebo | |||
| AFCAPS (women subgroup) , 1998 | Lovastatin 20–40 mg daily versus placebo | men and postmenopausal women without clinical evidence of cardiovascular disease (CVD) who had average low-density lipoprotein cholesterol and below average high-density lipoprotein cholesterol - subgroup of women | double blind Follow-up duration: 5.2 y US |
| lovastatin versus usual care | |||
| CLAPT, 1999 | lovastatin begun at 20 mg daily and tritrated up to 80 mg daily versus usual care | patients underwenting PTCA | open (blind assessement) Follow-up duration: 2.0 years |
| Sahni, 1991 | lovastatin 20-40mg/d versus conventional therapy alone | patients undergoing successful PTCA | open Follow-up duration: 2 years |
| low fat diet versus mediterranean-style diet | |||
| Tuttle, 2008 | low-fat versus Mediterranean-style diets | First MI survivors | open Follow-up duration: 24 months |
| MaxEPA versus control | |||
| Bellamy, 1992 | MaxEPA capsules (3g/d EPA + DHA) versus no treatment | people referred for coronary angioplasty | NA Follow-up duration: 7 months UK |
| Dehmer, 1998 | MaxEPA capsules, 18/d (5.4g EPA + DHA daily) versus no treatment | men undergoing coronary angioplasty imag | open Follow-up duration: 6 months US |
| Kaul, 1992 | MaxEPA capsules, 10/d (3g/d EPA + DHA) versus no treatment | people undergoing angioplasty | open Follow-up duration: 6 months India |
| MaxEPA versus placebo | |||
| Bairati, 1992 | MaxEPA, 15 capsules/d (4.5g EPA + DHA) versus placebo (olive oil, 15 capsules/d) | patients undergoing planned angioplasty | double blind Follow-up duration: 7 months Canada |
| Greenfield, 1993 | MaxEPA capsules, 12/d for first month, then 6/d (3.7g/d initially, then 1.9g EPA + DHAdaily), all with peppermint oil to disguise taste versus placebo (olive oil capsules, 12/d for first month, then 6/d. Looked like MaxEPA and had added peppermint oil) | people with stable ulcerative colitismag | double blind Follow-up duration: 6 months UK |
| Lau, 1993 | MaxEPA 10x 1g capsules daily (2.8g/d EPA + DHA) versus placebo (air-filled capsules, 10/d) | people with rheumatoid arthritisp | double blind Follow-up duration: 12 months UK |
| Lau, 1995 | MaxEPA 10x 1g capsules daily (2.8g/d EPA + DHA) versus placebo (air-filled capsules, 10/d) | people with rheumatoid arthritis | double blind Follow-up duration: 6 months Hong Kong |
| Nye, 1990 | MaxEPA capsules 12/d (2.2g EPA) versus placebo (olive oil capsules, 12/d, identical to MaxEPA) | people undergoing angioplasty | double blind Follow-up duration: 12 months New Zealand |
| Singh, 1997 | MaxEPA fish oil capsules 6/d (1.8g EPA + DHA) versus placebo (aluminium hydroxide 100 mg/d) | people with suspected acute MI | double blind Follow-up duration: 12 months India |
| Skoldstam, 1992 | MaxEPA fish oil capsules 10/d (3.0g/d EPA + DHA) versus placebo (vegetable oil capsules 10/d) | people with rheumatoid arthritis | double blind Follow-up duration: 6 months Sweden |
| Thien, 1993 | MaxEPA capsules, 18/d (5.4g/d EPA + DHA) versus placebo (olive oil capsules 18/d) | hayfever and asthma | double blind Follow-up duration: 6 months Australia |
| Mediterranean diet versus control | |||
| Lyon, | versus | ||
| Mediterranean diet with EOVV versus control | |||
| PREDIMED (olive oil), 2013 ISRCTN35739639 | Mediterranean diet supplemented with extra-virgin olive oil versus control diet (advice to reduce dietary fat) | participants who were at high cardiovascular risk, but with no cardiovascular disease | open Follow-up duration: 4.8 years Spain |
| Mediterranean diet with nuts versus control | |||
| PREDIMED (nuts), 2013 ISRCTN35739639 | Mediterranean diet supplemented with mixed nuts versus control diet (advice to reduce dietary fat) | participants who were at high cardiovascular risk, but with no cardiovascular disease | open Follow-up duration: 4.8 years Spain |
| Multiple risk factor interventions versus control | |||
| CELL, 1995 | intensive" health care advice through six group sessions versus usual care | subjects aged 30-59 years, with at least two cardiovascular risk factors in addition to moderately high lipid concentrations: total cholesterol > or = 6.5 mmol/l on three occasions, triglycerides < 4.0 mmol/l, and ratio of low density lipoprotein cholesterol to high density lipoprotein cholesterol > 4.0 | open Follow-up duration: 18 months |
| Family Heart, 1994 | Nurse led programme using a family centred approach with follow up according to degree of risk. Counselling on diet, weight, smoking, exercise, alcohol versus control | men aged 40-59 and their partners | double-blind Follow-up duration: 1 y UK |
| Göteborg Study, 1986 | multifactorial intervention programme on coronary heart disease versus no intervention | random sample of men age 47-55 y | open Follow-up duration: 11.8 yr Sweden |
| HDFP, 1979 NCT00000498 | Stepped care: Antihypertensive drugs, diet, smoking advice, weight control, exercise versus usual primary care | persons with high blood pressure | open Follow-up duration: 5 yr USA |
| Helsinki Businessmen Study, 1985 | Multifactorial prevention of cardiovascular diseases versus no intervention | healthy men 40-58 y at high risk | open Follow-up duration: 5 yr Finland |
| Johns Hopkins, 1983 | health education interventions versus control | hypertensives men and women | open Follow-up duration: 5 yr USA |
| Meland, 1997 | patient-centred, self-directive intervention of lifestyle changes in general practice versus conventional care | men with high coronary heart disease risk | open Follow-up duration: 1 y |
| MRFIT, 1982 NCT00000487?acronym= | special intervention (SI) program consisting of stepped-care treatment for hypertension, counseling for cigarette smoking, and dietary advice for lowering blood cholesterol levels versus no intervention | high-risk men aged 35 to 57 years | open Follow-up duration: 6 yr |
| Oslo, 1981 | recommendation to lower their blood lipids by change of diet and to stop smoking versus no intervention | healthy, normotensive men at high risk of coronary heart disease | open Follow-up duration: 5 yr Oslo, Norway |
| OXCHECK, 1994 | health checks by nurses versus no intervention | patients from general practice aged 35-64 years | open Follow-up duration: 3 yr UK |
| WHO Factories, 1982 | multifactorial prevention of coronary heart disease versus no intervention | men employed in 80 factories in Belgium, Italy, Poland, and the UK | open Follow-up duration: 6 years Belgium, Italy, Poland, and the UK |
| niacin versus control | |||
| VA drugs, 1968 | niacin versus | double blind Follow-up duration: 3.2 years | |
| niacin versus ezetimibe | |||
| ARBITER 6-HALTS (niacin vs ezetimibe), 2009 NCT00397657 | extended-release niacin 1 g/d, titrated to max tolerable dose up to 2 g/d (HDL-focused strategy) versus ezetimibe 10 mg/d (LDL-focused strategy) | patients with known coronary or vascular disease or coronary risk equivalents | open Follow-up duration: 14 months US |
| niacin versus placebo | |||
| CDP niacin, 1975 | niacin 3 mg/d versus placebo | Hommes, de 30 à 64 ans | double blind Follow-up duration: 6.2 years |
| niacin versus placebo (on top statin) | |||
| AIM-HIGH, 2011 NCT00120289 | high-dose, extended-release niacin in gradually increasing doses up to 2000 mg daily (+ simvastatin) versus placebo | patients with a history of cardiovascular disease, high triglycerides, and low levels of HDL cholesterol | double blind Follow-up duration: 32 months US, Canada |
| HPS 2-Thrive, NCT00461630 | 2 g of extended-release niacin and 40 mg of laropiprant versus placebo | patients with vascular disease | double blind Follow-up duration: 3.9y (median) UK, Scandinavia, China |
| Oxford Niaspan Study, 2009 NCT00232531 | niacin 2g daily (added to statin therapy) versus placebo (statins alone) | patients with low HDL-C (<40 mg/dl) and either a type 2 diabetes with coronary heart disease or a carotid/peripheral atherosclerosis | double blind Follow-up duration: 1 year USA |
| ARBITER 2, 2009 | long-acting niacin target dose of 1 g/day (added to statin therapy) versus placebo | patients with known coronary artery disease and well controlled on statin therapy | double blind Follow-up duration: 1 y USA |
| HATS, 2001 | simvastatin plus niacin versus placebo | patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels | double blind Follow-up duration: 3 y USA, Canada |
| niacin+colestipol versus control | |||
| UCSF SCOR, 1990 | Niacin 0–7.5 g colestipol 15–20 g versus Conventional therapy | patients with heterozygous familial hypercholesterolemia | Follow-up duration: 26 months |
| niacin+colestipol versus placebo | |||
| FATS, 1990 | niacin (1 g four times a day) and colestipol (10 g three times a day) versus placebo (or colestipol if the low-density lipoprotein [LDL] cholesterol level was elevated) | men no more than 62 years of age with apolipoprotein B levels greater than or equal to 125 mg per deciliter, documented coronary artery disease, and a family history of vascular disease | double-blind Follow-up duration: 2.5 years |
| niacin+ezetimibe versus simvastatin+ezetimibe | |||
| Guyton, 2008 | Niacin 2 g ezetimibe 10 mg simvastatin 20 mg versus Ezetimibe 10 mg simvastatin 20 mg | patients with type IIa or IIb hyperlipidemia | double-blind Follow-up duration: 24 weeks |
| nicoumalone or phenprocoumon versus placebo | |||
| ASPECT, 1994 | anticoagulant (nicoumalone or phenprocoumon) versus placebo | hospital survivors of myocardial infarction | Follow-up duration: 37 months |
| Omacor versus control | |||
| Eritsland, 1996 | Omacor capsules, 4/d (3.3g EPA + DHA daily) versus no treatment | people admitted for coronary bypass grafting | open Follow-up duration: 12 months Norway |
| GISSI-P, 1999 | Omacor gelatine capsules, 1/d (0.9g/d EPA + DHA daily) versus no treatment | people with recent myocardial infarction | open Follow-up duration: median 40 months Italy |
| Omacor versus placebo | |||
| Johansen, 1999 | Omacor capsules, 6/d (5g EPA + DHA daily) versus placebo (corn oil capsules, 6/d) | people about to undergo elective coronary angioplasty | double blind Follow-up duration: 6.5 months Norway |
| Nilsen, 2001 | Omacor capsules 4/d (3.5g EPA + DHA) versus placebo (corn oil capsules, 4/d) | people with acute myocardial infarction 4-8 days agoe/pj | double-blind Follow-up duration: 24 months Norway |
| omega-3 Fatty acids versus control | |||
| OMEGA, 2009 NCT00251134 | omega-3 fatty acids 1g daily (and standard medical therapy) versus standard medical therapy alone | Patients within 3-14 days after a non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI) | open Follow-up duration: 1 year Germany |
| omega-3 Fatty acids versus placebo | |||
| ALPHA OMEGA (EPA DHA), 2010 NCT00127452 | 400 mg per day supplement of the fish oil fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) via enriched margarines versus placebo | men and women with a history of myocardial infarction | double-blind Follow-up duration: 40 months the Netherlands |
| Risk and Prevention Study, 2013 NCT00317707.) | n-3 fatty acids (1 g daily)
versus placebo (olive oil) | men and women with multiple cardiovascular risk factors or atherosclerotic vascular disease but not myocardial infarction | double-blind Follow-up duration: 5 year (median) |
| omega-3 fatty acids versus placebo | |||
| GISSI HF fatty acid, 2008 NCT00336336. | n-3 polyunsaturated fatty acids (PUFA) 1 g daily
versus placebo | Patients with NYHA classes II to IV heart failure, whatever the cause and the LVEF and already receiving optimized recommended therapy with no clear indication or contraindication to cholesterollowering therapy | double blind Follow-up duration: 3.9y median (IQR 3-4.4) Italy |
| pactimibe versus placebo | |||
| CAPTIVATE, 2009 NCT00151788 | pactimibe 100mg daily versus placebo | patients with familial hypercholesterolemia and carotid atherosclerosis | double blind Follow-up duration: 15 months (mean) United States, Canada, Europe, South Africa, Israel |
| ACTIVATE, 2006 NCT00185042 | pactimibe 100 mg daily versus placebo | patients with angiographicallydocumented coronary disease | double blind Follow-up duration: 18 months |
| partial ileum bypass surgery versus no surgery | |||
| POSCH, 1990 NCT00000490 | partial ileum bypass surgery versus no surgery | survivors to a first myocardial infarction | open Follow-up duration: 9.7 years |
| phenprocoumon versus placebo | |||
| Breddin, 1980 | versus | patients who had survived a myocardial infarction for 30-42 days | double-blind |
| picotamide versus placebo | |||
| Cocozza, 1995 | picotamide 300 mg TID versus placebo | normotensive diabetic patients with asymptomatic mild or moderate nonstenotic (< 50%) carotid atherosclerotic lesions and negative history of cerebrovascular ischemic events | double blind Follow-up duration: 24 months Italy |
| Coto, 1989 | Picotamide 900 mg / j versus Placebo | patients with peripheral occlusive arterial disease of the lower limbs at functional stage II of the Fontaine classification | double blind Follow-up duration: 6 months |
| ADEP, 1993 | Picotamide 600 mg / j versus Placebo | patients with peripheral obstructive arterial disease (stade II+) | double blind Follow-up duration: 18 months |
| Neirotti, 1994 | Picotamide 900 mg / j versus Placebo | patients with peripheral arterial disease (PAD) at functional stage 2 of the Fontaine classification and with intermittent claudication for at least six months | double blind Follow-up duration: 18 months |
| Pikasol versus placebo | |||
| Bonnema, 1995 | Pikasol fish oil capsules, 6x1 g/d (3.3g EPA + DHA) versus placebo (olive oil capsules, 6x1 g/d) | people with insulin treated diabetes and microalbuminureakÒýÛ•£K | double-blind Follow-up duration: 24 months Denmark |
| pitavastatin versus atorvastatin | |||
| JAPAN ACS, 2009 NCT00242944 | pitavastatin 4 mg daily versus atorvastatin 20mg daily | patients with acute coronary syndrome undergoing IVUS-guided percutaneous coronary intervention | open Follow-up duration: 8-12 months Japan |
| policosanol versus control | |||
| Batista, 1996 | policosanol versus | Follow-up duration: 1.7 years | |
| Castano, 2001 | policosanol 10 mg twice daily versus placebo | intermittent claudication | double-blind Follow-up duration: 2 years |
| Más, 1999 | policosanol 5mg titrted up for 10mg daily versus placebo | patients with type II hypercholesterolemia and additional coronary risk factors | double-blind Follow-up duration: 24 weeks |
| polypill versus error | |||
| TIPS, 2009 NCT00443794 | Polycap versus Polycap components in eight formulations | subjects aged 45 to 80 years of age with at least one additional cardiovascular risk factor | double-blind Follow-up duration: 3 months |
| pravastatin versus control | |||
| FAST Fukuoka pravastatin, 2002 | pravastatin 10 mg/day versus control group (diet alone) | asymptomatic hypercholesterolemic patients | open Follow-up duration: 2 years Japan |
| MEGA, 2006 NCT00211705 | pravastatin 10 mg daily (20 mg per day if the total cholesterolconcentration did not decrease to 5·69 mmol/L or less) versus control | patients with hypercholesterolaemia (total cholesterol 5·69–6·98 mmol/L) and no history of coronary heart disease or stroke | open, blind assessment Follow-up duration: 5.3 y Japan |
| pravastatin versus placebo | |||
| LAMIL, 1997 | Pravastatin, 10-20 mg (starting at D3) versus Placebo | patients suffering an acute myocardial infarction | double blind Follow-up duration: 1 and 3 months Belgium |
| Pravastatin versus placebo | |||
| CARE (elderly subgroup), 1998 | Pravastatin 40mg versus | MI 3–20 months, subgroup of age 65-75 y | double blind Follow-up duration: 5.0y |
| pravastatin versus placebo | |||
| RECIFE, 1999 | Pravastatin, 40 mg versus Placebo | Patients with acute myocardial infarction or unstable angina and total cholesterol levels at admission >=5.2 mmol/L or LDL >=3.4 mmol/L | double blind Follow-up duration: 1.5 months Canada |
| Pravastatin versus placebo | |||
| LIPID (elderly sub group), 2001 | Pravastatin 40mg versus | MI or unstable angina, subgroup of age 65-75 y | double blind Follow-up duration: 6.1y |
| pravastatin versus placebo | |||
| PROSPER diabetic (sub group), 2002 | pravastatin 40mg daily versus placebo | mena and women aged 70–82 years with a history of, or risk factors for, vascular disease | double blind Follow-up duration: 3.2y mean |
| LIPID (diabetic sub group), 1998 | pravastatin 40 mg daily versus placebo | patients with a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter | double blind Follow-up duration: mean 6.1y Australia, New Zealand |
| CARE (diabetic sub group), 1998 | pravastatin versus placebo | men and postmenopausal women between 21 to 75 years of age, with MI between 3 and 20 months before randomization and plasma total cholesterol values <240mg/dL, LDL-C levels between 115 and 174mg/dL, and triglycerides <350mg/dL | |
| WOSCOPS (diabetic sub group), 1996 | pravastatin 40 mg daily versus placebo | men aged 45-64 years with no history of myocardial infarction and plasma total cholesterol concentrations of 6.5-8.0 mmol/L at initial screening | double blind Follow-up duration: mean 4.9y |
| PAIS, 2001 | Pravastatin, 40 mg (initiated within 48 hours of hospital admission) versus Placebo | patients with acute coronary syndromes | double blind Follow-up duration: 1 and 3 months The Netherlands |
| Pravastatin versus placebo | |||
| PLAC I (elderly sub group), 1995 | Pravastatin 40mg versus | Angiographic CAD or recent MI, subgroup of age 65-75 y | double blind Follow-up duration: 2.3y |
| REGRESS (elderly subgroup), 1995 | Pravastatin 40mg versus | Angiographic CAD, subgroup of age 65-70 y | double blind Follow-up duration: 2.0y |
| pravastatin versus placebo | |||
| PACT, 2004 | Pravastatin, 20-40 mg within 24 hours of the onset of symptoms in versus Placebo | patients with unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction within 24 hours of the onset of symptoms | double blind Follow-up duration: 1 months Australia |
| CAIUS, 1996 | pravastatin 40mg/d versus placebo | asymptomatic patients with hypercholesterolemia and at least one 1.3 < IMT < 3.5 mm in the carotid arteries | double blind Follow-up duration: 3 years Italy |
| CARE, 1996 | pravastatin 40 mg/d versus placebo | men and women with myocardial infarction who had plasma totalcholesterol levels below 240 mg per deciliter (mean,209) and low-density lipoprotein (LDL) cholesterollevels of 115 to 174 mg per deciliter | double blind Follow-up duration: 5 years USA, Canada |
| KAPS, 1995 | pravastatin 40mg/d versus placebo | Hypercholesterolemics men with serum LDL-C > or = 4.0 mmol/L and total cholesterol < 7.5 mmol/L | double blind Follow-up duration: 3 years Finland |
| LIPID, 1998 | pravastatin 40 mg/d versus placebo | patients with previous myocardial infarction or unstable angina and a baseline plasma cholesterol concentration of 4.0-7.0 mmol/L | double blind Follow-up duration: 6.1 years Australie et Nouvelle Zélande |
| PACT, 2004 | pravastatin initiated within 24 hours of onset of synmptoms and for 4 weeks versus placebo | patients with unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction <24 hours | double blind Follow-up duration: 30 days |
| PHYLLIS, 2004 | pravastatin (40 mg per day) versus placebo | hypertensive, hypercholesterolemic patients with asymptomatic carotid atherosclerosis | double-blind Follow-up duration: 2.6 y Italy |
| PLAC I, 1995 | pravastatin 40mg daily versus placebo | men and women with coronary artery disease and mild to moderate elevations in cholesterol levels | double blind Follow-up duration: 3 y United States |
| PLAC II, 1995 | pravastatin 20-40mg daily versus placebo | coronary patients (men and women ) | double blind Follow-up duration: 3 y United States |
| PMSG, 1993 | pravastatin 20 mg once daily versus placebo | patients with hypercholesterolemia(serum total cholesterol concentrations of 5.2 to 7.8 mmol/liter) and > or = 2 additional risk factors for atherosclerotic coronary artery disease | double blind Follow-up duration: 26 weeks |
| PREVEND IT, 2004 | pravastatin 40 mg daily versus placebo | subjects with microalbuminuria | double blind Follow-up duration: 46 months the Netherlands |
| PROSPER, 2002 | pravastatin 40mg daily versus placebo | men and women aged 70-82 years with a history of, or risk factors for, vascular disease | double blind Follow-up duration: 3.2 years Ecosse, Irelande, Pays bas |
| PROSPER (primary prevention subgroup), 2002 | pravastatin 40mg/d versus placebo | men and women aged 70-82 years with a history of, or risk factors for, vascular disease; primary prevention subgroup | double blind Follow-up duration: 3.2 years Ecosse, Irelande, Pays bas |
| REGRESS, 1995 | pravastatin 40 mg daily versus placebo | symptomatic men with normal to moderately elevated serum cholesterol levels | double blind Follow-up duration: 2 years Netherlands |
| WOSCOPS, 1995 | pravastatine 40 mg daily versus placebo | men aged 45-64 yr with no history of myocardial infarction and with raised plasma cholesterol levels (LDL cholesterol of at least 155 mg/dL, total cholesterol of at least 252 mg/dL) | double blind Follow-up duration: 4.9 years Scotland |
| Pravastatin versus placebo | |||
| ALLHAT (women subgroup) , 2002 | Pravastatin 40 mg daily versus control | Ambulatory persons, aged 55 years or older, with low-density lipoprotein cholesterol (LDL-C) of 120 to 189 mg/dL (100 to 129 mg/dL if known CHD) and triglycerides lower than 350 mg/dL- subgroup of women | open Follow-up duration: 4.8 y US |
| MEGA (women subgroup) , 2006 | Pravastatin 10–20 mg daily versus control | patients with hypercholesterolaemia (total cholesterol 5.69-6.98 mmol/L) and no history of coronary heart disease or stroke- subgroup of women | open Follow-up duration: 5.3 y Japan |
| pravastatin versus usual care | |||
| L-CAD, 2000 | Pravastatin, 20-40 mg (strating on average at D6) versus Usual care | patients with acute coronary syndrome | open Follow-up duration: 1, 4, and 6 months Germany |
| GISSI P (diabetic sub group), 2000 | pravastatin 20 mg daily versus usual care | recent acute myocardial infarction patients (< or = 6 months) with total blood cholesterol > or = 200 mg/dl | open Follow-up duration: median 24.3 months |
| ALLHAT-LLT (diabetic sub group), 2002 | pravastatin versus usual care | Ambulatory persons aged 55 years or older, with lowdensity lipoprotein cholesterol (LDL-C) of 120 to 189 mg/dL (100 to 129 mg/dL if known CHD) and triglycerides lower than 350 mg/dL | open |
| PTT, 2002 | Pravastatin, 40 mg versus Usual care | patients who underwent coronary balloon angioplasty of the infarct-related artery during the first month of acute myocardial infarction | open Follow-up duration: 1 and 6 months Turkey |
| ALLHAT, 2002 NCT00000542 | pravastatin 40mg/d versus usual care | aged 55 years or older, moderately hypercholesterolemic, hypertensive participants with at least 1 additional CHD risk factor | open Follow-up duration: 4.8 years USA, Puerto Rico, Canada |
| OACIS-LIPID, 2008 | pravastatin 10 mg/daily versus no pravastatin | patients with AMI who had plasma total cholesterol levels of 200-250 mg/dl and triglyceride levels <300 mg/dl | open Follow-up duration: 9 months |
| GISSI Prevenzione, 2000 | low-dose pravastatin regimen 20 mg daily versus control | recent acute myocardial infarction patients (<= 6 months) with total blood cholesterol >= 200 mg/dl and < 250 mg/dl and after a period of 3–6 months showed plasma cholesterol levels >=200 mg/ dL despite adequate dietary recommendations | open Follow-up duration: 23 months (mean) Italy |
| KLIS, 2000 | pravastatin 10-20 mg/day versus conventional treatment | Japanese men aged 45-74 years with serum total cholesterol of > or = 220 mg/dl (5.69 mmol/l), primary prevenion | open Follow-up duration: 5 years Japan |
| pravastatin high dose versus pravastatin | |||
| PROVE IT TIMI 22 (diabetic sub group), 2006 | pravastatin 80mg daily versus pravastatin 40mg daily | patients hospitalized for an acute coronary syndrome within the preceding 10 days | double blind Follow-up duration: 24 months mean |
| probucol versus control | |||
| FATS Fukosawa (probucol), 2002 | probucol 500 mg/day versus diet alone | asymptomatic patients with hypercholesterolemia | open Follow-up duration: 2 years Japan |
| probucol versus placebo | |||
| PQRST, 1994 | Probucol 1 g / j pendant 3 ans versus placebo, de même aspect(2 tablettes par jour)pendant 3 ans | Stade II: 70% | Double aveugle Follow-up duration: 3 ans |
| Probucol versus placebo | |||
| McCaughan, 1981 | probucol versus placebo | hypercholesterolemic men | double-blind Follow-up duration: 1 year |
| probucol versus placebo | |||
| PQRST, 1994 | probucol 0.5 g twice daily versus placebo | hypercholesterolemic patients with visible atherosclerosis | double blind Follow-up duration: 3 y |
| Probucol versus placebo | |||
| Tardif, 1997 | probucol 500 mg versus placebo | patients undergoing PTCA | open Follow-up duration: 0.5 years |
| Promega versus control | |||
| Milner, 1989 | Promega 9 capsules/d (4.5g EPA + DHA) versus no treatment | people about to undergo angioplasty | open with blind assessment Follow-up duration: 6 months US |
| Promega versus placebo | |||
| Connor, 1993 | Promega oil, 15g/d (6g/d EPA + DHA) versus placebo (Olive oil, 15g/d) | people with non-insulin dependant diabetes and hypertiglyceridaemia | double-blind Follow-up duration: 6 months US |
| Sacks (HARP), 1995 | Promega capsules 12x1 g/d (6.0g EPA + DHA + DPA) versus placebo (olive oil capsules, 12x1 g/d) | people with angiographically documented CHD DPA) | double-blind Follow-up duration: 29 months US |
| PurEPA versus placebo | |||
| Belluzzi, 1996 | PurEPA 3 enteric coated capsules/d (0.9g EPA + DHA) versus placebo (Mixed TG 3 enteric coated capsules) | established Crohn’s disease, in remission | double-blind Follow-up duration: 12 months Italy |
| rimonabant versus placebo | |||
| STRADIVARIUS, 2008 NCT00124332 | rimonabant 20 mg daily versus placebo | patients with abdominal obesity and the metabolic syndrome | double-blind North America, Europe, and Australia |
| CRESCENDO, 2010 NCT00263042 | rimonabant 20 mg versus placebo | patients patients with abdominal obesity and with previously manifest or increased risk of vascular disease | double-blind Follow-up duration: 13.8 months 42 countries |
| rimonabant 20mg versus placebo | |||
| RIO europe 20mg, 2005 | rimonabant 20mg daily versus placebo | patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or bothtž-dt | Double blind Europe and USA |
| Rio-lipid 20 mg, 2005 | rimonabant 20 mg daily versus placebo | overweight or obese patients (body-mass index 27 to 40) with untreated dyslipidemia (triglyceride levels >1.69 to 7.90 mmol per liter, or a ratio of cholesterol to high-density lipoprotein [HDL] cholesterol of >4.5 among women and >5 among men) | Double blind Follow-up duration: 12 months worlwide (8 countries) |
| RIO-North America 20 mg, 2006 NCT00029861 | rimonabant 20mg daily versus placebo | obese (body mass index >=30) or overweight (body mass index >=27 and treated or untreated hypertension or dyslipidemia) adult patients | Double blind US and Canada |
| rimonabant 20mg versus rimonabant 5mg | |||
| RIO europe (20 vs 5 mg), 2005 | versus | ||
| rimonabant 5mg versus placebo | |||
| RIO europe 5mg, 2005 | 5 mg rimonabant versus placebo | patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or both | double-blind Follow-up duration: 1 y |
| rivaroxaban versus aspirin | |||
| COMPASS (rivaroxaban alone), 2017 NCT01776424 | Rivaroxaban 2.5 mg twice daily alone versus aspirin 100 mg once daily | Patients With Coronary or Peripheral Artery Disease | |
| rivaroxaban + aspirin versus aspirin | |||
| COMPASS (rivaroxaban + aspirin), 2017 NCT01776424 | rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily) versus aspirin 100 mg once daily | Patients With Coronary or Peripheral Artery Disease | double-blind Follow-up duration: 23 months |
| rosuvastatin versus placebo | |||
| JUPITER (elderly sub group), 2009 | rosuvastatin 20mg daily versus placebo | healthy individuals aged >=70 years with normal LDL cholesterols but with CRP levels >=2.0 mg/dL | double blind Follow-up duration: double-blind |
| ASTRONOMER, 2010 ISRCTN 32424163 | rosuvastatin 40 mg daily versus placebo | asymptomatic patients with mild to moderate aortic stenosis and no clinical indications for cholesterol lowering | double blind Follow-up duration: 3.5 y |
| AURORA, 2009 | rosuvastatin 10 mg daily versus placebo | in patients with end-stage renal disease on hemodialysis | double blind Follow-up duration: 3.2 y mean (max 5.6y) |
| HOPE 3, 2016 NCT00468923 | rosuvastatin 10 mg per day versus placebo | subjects who did not have cardiovascular disease and were at intermediate risk | double-blind Follow-up duration: 5.6 years 21 countries |
| CORONA, 2007 NCT00206310 | rosuvastatin 10mg/d versus placebo | patients at least 60 years of age with NYHA class II, III, or IV ischemic, systolic heart failure | double blind Follow-up duration: 32.9 months median |
| Krum, 2007 | rosuvastatine 40mg/d versus placebo | patients with systolic (LVEF<40%) CHF of ischemic or nonischemic etiology | double blind Follow-up duration: 6 months Australia |
| GISSI-HF rosuvastatine, 2008 NCT00336336 | low-dose rosuvastatin 10 mg daily versus placebo | Patients with NYHA classes II to IV heart failure, whatever the cause and the LVEF and already receiving optimized recommended therapy with no clear indication or contraindication to cholesterollowering therapy | double blind Follow-up duration: 3.9y median (IQR 3-4.4) Italy |
| JUPITER, 2008 NCT00239681 | rosuvastatin 20 mg daily versus placebo | apparently healthy individuals with low LDL-cholesterol levels of less than 130 mg per deciliter but elevated C-reactive-protein (high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher) | double blind Follow-up duration: median 1.9 year 26 countries |
| METEOR, 2007 NCT00225589 | rosuvastatin 40mg daily versus placebo | individuals, with either age (mean, 57 years) as the only coronary heart disease risk factor or a 10-year Framingham risk score of less than 10%, modest CIMT thickening (1.2-<3.5 mm), and elevated LDL cholesterol | double-blind USA, Europe |
| Rosuvastatin versus placebo | |||
| JUPITER (women subgroup) , 2008 | Rosuvastatin 20 mg daily versus placebo | apparently healthy men and women with low-density lipoprotein cholesterol levels of less than 130 mg/dL and high-sensitivity C-reactive protein levels of 2.0 mg/L or higher - subgroup of women | double-blind Follow-up duration: 1.9 y 26 countries |
| simvastatin versus control | |||
| Hong, 2005 | simvastatin versus no treatment | patients with ischemic heart failure who underwent percutaneous coronary intervention (PCI) for acute myocardial infarction (left ventricular [LV] ejection fraction <40%) | open Follow-up duration: 1 year |
| simvastatin versus ezetimibe | |||
| Landmesser, 2005 | simvastatin 10mg/d versus ezetimibe 10mg/d | patients with chronic heart failure | |
| simvastatin versus placebo | |||
| 4S, 1994 | simvastatin 20 or 40 mg/d, target CT between 3 et 5.2 mmol/l versus placebo | patients with angina pectoris or previous myocardial infarction and serum cholesterol 5.5-8.0 mmol/L on a lipid-lowering diet | double blind Follow-up duration: 5.4 years Scandinavia |
| Mondillo, 2003 | simvastatine: 40 mg/ jour pendant 6 mois. versus placebo | Stade de la maladie: II. | Double aveugle Follow-up duration: 6 mois |
| Aronow , 2003 | simvastatine 40 mg/j versus placebo | Stade II | Non déterminable Follow-up duration: 1 an |
| HPS (diabetic sub group), 2002 | simvastatin 40mg daily versus placebo | Men and women diabetes aged about 40–80 years with non-fasting blood total cholesterol concentrations of at least 3·5 mmol/L (135 mg/dL) | double blind |
| 4S (diabetic sub group), 1999 | simvastatin versus placebo | diabetic men and women aged 35 to 70 years with previous MI or active, stable angina pectoris and with serum total cholesterol level between 5.5 to 8.0 mmol/L and serum triglyceride level <=2.5 mmol/L | double blind Follow-up duration: 5.4y Denmark, Finland, Iceland, Norway, and Sweden |
| 4S (elderly subgroup), 1997 | Simvastatin 20-40mg versus | MI 6 months or stable angina, subgroup of age 65-70 y | double blind Follow-up duration: 5.4y |
| HPS (elderly subgroup), 2002 | Simvastatin 40mg versus | Vascular disease or diabetes, subgroup of age 65-80 y | double blind Follow-up duration: 5.0y |
| Node, 2003 | simvastatin 10mg/d versus placebo | patients with symptomatic, nonischemic, dilated cardiomyopathy | |
| HPS (post troke sub group), 2004 | simvastatin 40mg daily versus placebo | adults with cerebrovascular disease, total cholesterol >=3·5 mmol/L and without coronaro disease (n=1820) | double blind |
| A to Z, 2004 | Simvastatin, 40-80 mg early initiation versus Placebo | patient with an acute coronary syndrome (ACS) | Double aveugle Follow-up duration: 4 months 41 countries |
| Ren, 2009 | simvastatin (40 mg/d for 4 weeks) versus placebo | patients with unstable angina pectoris | double-blind |
| CIS, 1997 | simvastatin 40 mg versus placebo | men with documented coronary artery disease and hypercholesterolaemia | double blind Follow-up duration: 2.3 years |
| HPS, 2002 | simvastatin 40 mg/d versus placebo | adults (aged 40-80 years) with coronary disease, other occlusive arterial disease, or diabete | double blind Follow-up duration: 5 years UK |
| HPS (diabetic primary prevention sub group), 2003 | simvastatin 40 mg/d versus placebo | adults (aged 40-80 years) with diabetes (primary prevention subgroup) | double blind Follow-up duration: 5 years UK |
| MAAS, 1994 | simvastatin 20 mg daily versus placebo | patients with coronary heart disease | double blind Follow-up duration: 4 y |
| Simvastatin versus placebo | |||
| HPS (women subgroup) , 2002 | Simvastatin 40 mg versus placebo | UK adults (aged 40-80 years) with coronary disease,other occlusive arterial disease, or diabetes - subgroup of women without CHD | double blind Follow-up duration: 5 y UK |
| simvastatin high dose versus simvastatin | |||
| SEARCH, 2010 NCT00124072 | simvastatin 80 mg daily versus simvastatin 20mg daily | MI survivors | Follow-up duration: 6.7 years (mean) |
| sodium reduction versus control | |||
| HPT, 1990 | dietary counseling versus no dietary counseling | normotensive healthy men and women aged 25 to 49 years, with diastolic blood pressures of 78 to 89 mm Hg | open Follow-up duration: 3 years USA |
| TOHP I, 1992 | sodium reduction versus unmasked nonintervention controls | men and women, aged 30 through 54 years, with diastolic blood pressure from 80 through 89 mm Hg | open Follow-up duration: 18 months USA |
| TOHP II, 1997 | sodium reduction intervention versus control | overweight people with high-normal blood pressure | open Follow-up duration: 3-4 years USA |
| Chang, 2006 | potassium-enriched salt versus control | elderly veterans | open Follow-up duration: 31 mo USA |
| Morgan, 1978 | moderate restriction of salt versus control | patients with a diastolic blood-pressure between 95 and 109 mm Hg | open Follow-up duration: 2 years Australia |
| TONE, 1998 | reduced sodium intake versus control | older persons with hypertension | open Follow-up duration: 29 months USA |
| Alli, 1992 | low-sodium diet versus usual diet | previously undiagnosed mildly hypertensive patients | open Follow-up duration: 12 months Italy |
| Arroll, 1995 | salt restriction versus without salt restriction | healthy adult volunteers with a sedentary lifestyle and on pharmacological therapy for hypertension | open Follow-up duration: 6 months New Zealand |
| Costa, 1981 | low-salt diet versus control | young patients with borderline hypertension | open Follow-up duration: 12 months Italy |
| DISH, 1985 | sodium-restriction versus control | normotensive subject | open Follow-up duration: 56 weeks |
| Kumanyika, 1993 | reduce dietary sodium to 80 mmol (1800 mg)/24 h versus | ||
| Morgan, 1987 | reduced sodium intake versus control | hypertensive patients previously well-controlled on drug therapy | open Follow-up duration: 6 months Australia |
| Paterna, 2008 | low-sodium diet plus oral furosemide (250-500 mg, b.i.d.) versus normal-sodium diet plus oral furosemide 250-500 mg, b.i.d. (twice a day) and fluid intake of 1000 ml per day | compensated CHF patients | open Follow-up duration: 180 days |
| Silman, 1993 | restricted sodium diet versus control | patients who had a sustained diastolic blood pressure of 95 to 104 mm Hg and who had no treatment for it for at least 13 months before the trial | open Follow-up duration: 13 months UK |
| Thaler, 1982 | salt-restriction versus control | subjects aged 64 or less with a systolic blood pressure 138-179 mmHg including those on antihypertensive treatment | open New Zealand |
| strategy to increase HDL cholesterol versus placebo | |||
| AFREGS, 2005 | Niacin 0.25–3 g gemfibrozil 1.2 g cholestyramine 2 g versus placebo | military retirees younger than 76 years of age with low HDL cholesterol levels and angiographically evident coronary disease | double-blind Follow-up duration: 30 months |
| succinobucol versus placebo | |||
| ARISE, 2008 NCT00066898 | succinobucol 300 mg once daily versus placebo | patients with recent (14-365 days) acute coronary syndromes already managed with conventional treatments | double blind Follow-up duration: 24 mo (range 12-36 mo) Canada, US, UK, South Africa |
| sulfinyrazone versus placebo | |||
| Dutch, 1980 | sulfinyrazone versus | Follow-up duration: 32 months | |
| suloctidil versus placebo | |||
| Adriaensen, 1976 | Suloctidil 200 mg / j versus Placebo | patients suffering from intermittent claudication ( stade II) | double blind Follow-up duration: 2 months |
| Verhaeghe, 1981 | Suloctidil 200 mg / j versus Placebo | patients with intermittent claudication (stade II) | double blind Follow-up duration: 6 months |
| Jones, 1982 | Suloctidil 300 mg / j versus Placebo | patients suffering from intermittent claudication (stade II) | double blind Follow-up duration: 6 months |
| Holm, 1984 | Suloctidil 300 mg / j versus Placebo | AOMI stade II | double blind Follow-up duration: 2.75 y |
| Super EPA versus placebo | |||
| Reis, 1991 | Super EPA capsules 12x1 g/d (7.0g EPA + DHA + a-lin) ORPromega capsules 12x1 g/d (6.0g EPA + DHA + a-lin) versus placebo (olive oil capsules, 12x1 g/d) | people undergoing angioplasty | double blind Follow-up duration: 6 months US |
| thyroxine versus placebo | |||
| CDP tyroxine, 1975 | thyroxine versus placebo | Follow-up duration: 3.0 years | |
| ticagrelor versus clopidogrel | |||
| EUCLID, 2016 NCT01732822 | ticagrelor (90 mg twice daily) versus clopidogrel (75 mg once daily) | patients with symptomatic peripheral artery disease | Follow-up duration: 30 months (median) |
| ticagrelor versus placebo (on top aspirin) | |||
| PEGASUS 60mg, 2015 NCT01225562 | ticagrelor at a dose of 60 mg twice daily versus placebo | patients who had had a myocardial infarction 1 to 3 years earlier | double-blind Follow-up duration: 2.75 y (median) |
| PEGASUS 90mg, 2015 NCT01225562 | ticagrelor at a dose of 90 mg twice daily
versus | patients who had had a myocardial infarction 1 to 3 years earlier | double-blind Follow-up duration: 2.75 y (median) |
| ticlopidine versus placebo | |||
| Ellis, 1986 | Ticlopidine 500 mg/j versus Placebo | AOMI stade II | double blind Follow-up duration: 6 months |
| Hurlow, 1980 | Ticlopidine : 100 -500 mg / jour pendant 2 mois. versus Placebo | Données non disponibles | double blind |
| Berglund, 1985 | ticlopidine 500 mg daily versus placebo | middle-aged men with stable incapacitating angina pectoris | double blind Follow-up duration: 2m |
| Krause, 1980 | Ticlopidine : 500 mg pendant 4 mois versus Placebo | Données non disponibles | double blind |
| Birmingham-A, 1979 | ticlopidine 100, 250, 500 mg versus | Follow-up duration: 2 months | |
| Katsumara, 1982 | Ticlopidine 500 mg/j versus Placebo | patients with ischemic ulcers due to chronic arterial occlusion | double blind Follow-up duration: 6 semaines |
| London diabetes, 1983 | ticlopidine 500mg versus | Follow-up duration: 12 months | |
| Aukland, 1982 | Ticlopidine 500 mg/j versus Placebo | men with atherosclerotic intermittent claudication and haemorheological abnormalities | double blind Follow-up duration: 1 y |
| TIMAD, 1984 | ticlopidine 500mg versus | Follow-up duration: 32m | |
| Stiegler, 1984 | Ticlopidine 500 mg/j versus Placebo | AOMI stade II | double blind |
| BTRS, 1992 | ticlopidine 500mg/d versus placebo | insulin-treated diabetics with background retinopathy | double blind Follow-up duration: 48 months |
| Nyberg, 1984 | ticlopidine 500mg daily versus placebo | insulin dependent diabetes complicated by nephropathy | double blind Follow-up duration: 12 months |
| Cloarec, 1986 | Ticlopidine 500 mg/j versus Placebo | AOMI stade non précisé | double blind Follow-up duration: 1 y |
| Arcan, 1988 | Ticlopidine 500 mg/j versus Placebo | patients with chronic intermittent claudication due to obstructive peripheral vascular disease (stade II) | double blind Follow-up duration: 6 months |
| Balsano, 1989 | Ticlopidine 500 mg/j versus Placebo | patients with intermittent claudication (stade II) | double blind Follow-up duration: 21 months |
| STIMS, 1990 | Ticlopidine 500 mg/j versus Placebo | patients with intermittent claudication (stade II) | double blind Follow-up duration: 5.6 y |
| EMATAP, 1993 | Ticlopidine 500 mg/j versus Placebo | AOMI stade non précisé | double blind |
| torcetrapib versus placebo | |||
| RADIANCE 1, 2007 NCT00136981 | atorvastatin combined with 60 mg of torcetrapib versus atorvastatin monotherapy | patients with heterozygous familial hypercholesterolemia | open Follow-up duration: 24 months |
| ILLUMINATE, 2007 NCT00134264 | torcetrapib 60mg daily plus atorvastatin (at a dose established during the runinperiod) versus atorvastatin alone | patients at highcardiovascular risk | double blind Follow-up duration: 1.52y 7 countries |
| RADIANCE 2, 2007 | torcetrapib 60mg daily (on top of atorvastatin attitrated dose) versus placebo +atorvastatin attitrated dose | patients with mixed dyslipidaemia | double blind Follow-up duration: 24 months North America and Europe |
| ILLUSTRATE, 2007 NCT00134173 | atorvastatin plus 60 mg of torcetrapib daily versus atorvastatin monotherapy | patients with coronary disease | open Follow-up duration: 24 months North America and Europe |
| various drugs versus placebo | |||
| HARP, 1994 NCT00000461 | Various drugs (pravastatin, nicotinic acid, cholestyramine, and gemfibrozil stepwise as needed to reach the specified goal (total cholesterol < or = 4.1 mmol/L, ratio of LDL/high-density-lipoprotein [HDL] cholesterol < or = 2.0) versus placebo | normocholesterolaemic patients with coronary heart disease | open Follow-up duration: 2.5 years |
| various drugs versus usual care | |||
| SCRIP, 1994 NCT00000508 | multifactor risk reduction (Various drugs) versus usual care | patients with angiographically defined coronary atherosclerosis | open Follow-up duration: 4.0 years |
| vit B6 versus control | |||
| NORVIT (vit B6) (Bonaa), 2006 NCT00266487 | vit B6 40 mg daily
versus no vit B6 | men and women who had had an acute myocardial infarction within seven days | double-blind Follow-up duration: 36 months Norway |
| vit B6 versus placebo | |||
| WENBIT (vit B6), 2008 NCT00354081 | vit B6 40mg daily
versus placebo | adult participants undergoing coronary angiography | double blind Follow-up duration: 38.4 mo Norway |
| vitamin C versus placebo | |||
| PHS II vitamin C, 2008 NCT00270647 | vitamin C 500mg daily versus placebo | US male physicians aged 50 years or older | double blind Follow-up duration: 8 years (mean) US |
| WACS vitamin C, 2007 NCT00000541 | vitamin C (ascorbic acid) 500 mg/d
versus placebo | female health professionals at increased risk (40 years or older with a history of CVD or 3 or more CVD risk factors) | double blind Follow-up duration: 9.4 years US |
| vitamin E versus control | |||
| GISSI, 1999 | vitamin E 300mg/d versus no vitamine E | patients with recent (3 months) myocardial infarction | open Follow-up duration: 3.5y Italy |
| PPP, 2001 | vitamin E (300 mg/day) versus no vitamin E | men and women aged 50 years or greater, with at least one of the major recognised cardiovascular risk factors | open Follow-up duration: 3.6y Italy |
| vitamin E versus placebo | |||
| CHAOS, 1996 | vitamin E 400-800UI/d (alpha tocopherol) versus identical placebo | patients with angiographically proven coronary atherosclerosis | double-blind Follow-up duration: 1.5y UK |
| SPACE, 2000 | vitamin E 800 IU daily versus matching placebo | Haemodialysis patients aged 40–75 years with pre-existing cardiovascular disease | double -blind Follow-up duration: 1.42 years Israel |
| HOPE, 2000 | vitamin E 400IU/d from natural sources versus matching placebo | women and men 55 years of age or older who were at high risk for cardiovascular events because they had cardiovascular disease or diabetes in addition to one other risk factor. | double-blind Follow-up duration: 4.5y Multinational: Canada, USA, Europe, South America |
| ATBC vitamin E, 1994 | vitamin E (alpha-tocopherol) 50mg/d
versus placebo | male smokers 50 to 69 years of age from southwestern Finland | double-blind Follow-up duration: 6.1 median (range 5-8y) Southwestern Finland |
| WACS vitamin E, 2007 NCT00000541 | vitamin E (600IU every two days)
versus placebo | female health professionals at increased risk (40 years or older with a history of CVD or 3 or more CVD risk factors) | double blind Follow-up duration: 9.4 years US |
| WHS vitamin E, 2005 NCT00000479 | vitamin E 600 IU every other day (á-tocopherol) versus placebo | apparently healthy US women aged at least 45 years | double-blind Follow-up duration: 10.1 y US |
| PHS II vitamin E, 2008 NCT00270647 | vitamin E 400IU every two days
versus placebo | US male physicians aged 50 years or older | double blind Follow-up duration: 8 years (mean) US |
| HOPE renal insufficiency subgroup, 2004 | vitamin E 400 IU/day, natural versus placebo | patients with either known cardiovascular disease or diabetes and at least one additional coronary risk factor and renal insufficiency (sub group) | double-blind Follow-up duration: 4.5y North and South America, Europe |
| ASAP, 2000 | d-alpha-tocopherol 91 mg (136 IU) twice daily versus placebo | smoking and nonsmoking men and postmenopausal women aged 45-69 years with serum cholesterol >= 5.0 mmol/l | double-blind Follow-up duration: 3 years Finland |
| ATBC 2nd prev subgroup (vitamin E), 1998 | alpha tocopherol (vitamin E)
50 mg/day versus placebo | patients enroled in the ATBC trial and who had angina pectoris in the Rose chest pain questionnaire at baseline | double-blind Follow-up duration: 3.79 y Finland |
| AREDS, 2001 | daily supplementation of antioxidants (500 mg of vitamin C, 400 IU of vitamin E, and 15 mg of beta carotene) versus placebo | patients with age-related lens opacities and visual acuity loss | double-blind Follow-up duration: 6.3 y USA |
| Linxian, 1993 | beta carotene, vitamin E, and selenium versus | Apparently healthy Individuals of ages 40-69 | Follow-up duration: 5y |
| vorapaxar versus placebo (on top aspirin) | |||
| TRA-2P TIMI 50, 2012 NCT00526474 | vorapaxar (SCH 530348) 2.5-mg daily versus placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel) | patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease) | double-blind Follow-up duration: 2.5 y (median) |
| TRA-2P TIMI 50 (no prior stroke sub group), 2012 | vorapaxar (SCH 530348) 2.5-mg daily
versus placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel) | patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease), sub group of patient with no prior stroke | double-blind Follow-up duration: 2.5 y (median) |
| TRA-2P TIMI 50 (MI subgroup), 2012 NCT00526474 | vorapaxar (SCH 530348) 2.5-mg daily
versus placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel) | prespecified subgroup of patients with a qualifying myocardial infarction among the overall population of patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease) | double-blind Follow-up duration: 2.5 y (median) multinational |
| warfarin versus placebo | |||
| Thrombosis Prevention trial (Warfarin), 1998 NCT00000614 | warfarin started at 2.5mg/d adjusted for a target INR 1.5
versus placebo | men aged between 45 years and 69 years at high risk of IHD | double blind Follow-up duration: median 6.8 y UK |
| WARIS, 1990 | warfarin versus placebo | patients who had recovered from acute myocardial infarction (mean interval from the onset of symptoms to randomization, 27 days) | double-blind Follow-up duration: 37 months |
| warfarin + aspirin versus placebo | |||
| Thrombosis Prevention trial (W plus A), 1998 NCT00000614 | warfarin adjusted dose for INR of 1.5 + aspirin 75 mg daily
versus placebo | men aged between 45 years and 69 years at high risk of IHD | double blind Follow-up duration: median 6.8 y UK |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
